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ABSTRACT 
Treatment of atrophic long bone fracture nonunion is challenging with current 
therapeutic interventions including bone morphogenetic proteins (BMPs) or 
autologous mesenchymal stem cells (MSCs). In this work it was hypothesised 
that, total MSC numbers and their responsiveness to BMPs in the nonunion 
setting were compromised, leading to poor healing. Additionally, the rationale 
for systemic injection of MSCs to repair bone is based on a contentious concept 
of their widespread circulation. To address the number and functional 
competence of iliac crest bone marrow MSCs in nonunion, this study employed 
colony forming unit fibroblast and osteoblast assays (CFU-F, CFU-O) and flow 
cytometry enumeration of the CD4SIowCD271 + cell population, to compare 
nonunions (n=11) with united long bone fracture patients (n=11). Unexpectedly, 
total number of MSCs, was higher in nonunion; however their proliferative 
capacity, was lower. No response to BMP-7, assessed by CFU-F, CFU-O and 
calcium deposition assays, was found in both nonunion and union study groups. 
Possible mechanical translocation of MSCs into the venous circulation was 
investigated using matched antecubital venous blood from the upper limb (Ul) 
and lower limb. femoral venous blood (ll) samples from nonunion patients 
undergoing reaming with reamer irrigation aspiration (RIA) (n=12) and other 
non-reaming procedures (NR, n=12) with control groups including Ul from early 
rheumatoid arthritis (RA, n=11) and healthy controls (n=12). CFU-F assay 
results revealed the presence of MSC colonies in II at higher frequencies than 
Ul samples in RIA and NR, (8ll, 2PB) and (Sll, 1 PB) respectively. None were 
detected in the Ul of RA and controls. 
Altogether, these results indicate a functional defect in proliferative capacity of 
MSCs in nonunion. MSCs however are unlikely to circulate and contribute to 
reduced healing at fracture sites. This points towards a generalized systemic 
effect of the nonunion state on MSC dynamics, which should be further 
explored in future. 
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CHAPTER 1 
FRACTURE HEALING AND 
FRACTURE NONUNION IN 
LONG BONES 
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1.1 INTRODUCTION 
Bone is a metabolically active connective tissue under constant regulation by a 
variety of biochemical, biomechanical, cellular and hormonal factors. Under 
normal conditions, these factors play an important role in the maintenance of 
bone integrity and are key players in the regulation of fracture repair [1]. Due to 
its rigid nature, bone is vital for mechanical support, locomotion and protection 
of vital b~dy organs. Its high calcium content makes it a reservoir for calcium 
and hence is extremely important for calcium homeostasis. Bone marrow (BM) 
present inside bone medullas is the main site of hematopoiesis in adults [2]. 
A bone fracture is a disruption in the continuity of bone. This can range from 
microscopic discontinuity to a multi-fragmented (comminuted) break. As the 
spectrum of fractures is vast, classification systems have been used to 
accurately describe them. Fracture classification systems provide a unified 
language to accurately describe fractures, facilitate the placement of guidelines 
for optimal fracture management and help in predicting fracture outcomes. 
Numerous classification systems have been proposed to describe long bone 
fractures in adults. They maybe be classified based on their anatomical location 
within a bone (metaphyseal, diaphyseal, or epiphyseal). Based on fracture 
geometry they may be referred to as displaced or undisplaced, transverse, 
spiral, segmental or comminuted. Fractures inside joints are known as intra-
articular fractures whereas those not involving joints are described as extra-
articular. 
A fracture maybe classified as "open" or "closed". An open fracture is one which 
has a wound that connects the fracture site to the outside environment. These 
fractures are at a higher risk of infection and nonunion. In a closed fracture, the 
skin remains intact and therefore there is no communication between the 
fracture site and the outside environment [3]. One of the most commonly used 
systems to describe open fractures is the Gustilo and Anderson classification 
(Table 1.1) [4]. 
3 
Table 1.1: The Gustilo and Anderson classification for open fractures 
Grade 
Grade I 
Grade II 
Grade III 
Grade 
ilia 
Grade 
IIIb 
Grade 
IIIc 
Description 
Clean wound S 1 cm, usually from inside out. Minimal soft 
tissue damage 
Moderately contaminated wound >1 cm. Slight or moderate 
soft tissue damage 
Extensive soft tissue damage, usually due to high velocity 
injury and I or severe crush injury 
Soft tissue coverage of the fractured bone is adequate 
Extensive soft tissue injury requiring a flap to cover the 
exposed bone 
Any open fracture that is associated with arterial injury 
necessitating repair. 
Based on their aetiology, fractures maybe classified into four groups [5]. 
1- Fractures caused only by a sudden injury. These are the most 
common types of fractures. They occur in healthy bone when a strong 
force exceeding the strength of the affected bone is applied. This force 
may be direct (when the force hits the bone directly) or indirect (when the 
force is transmitted along the bone_' to cause fracture elsewhere in the 
bone). 
2- Fragility fractures. These fractures are associated with generalised 
bone weakness (e.g. osteoporosis). Since the affected bone is already 
weakened by the disease, less force is required to cause the fracture. 
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3- Fatigue (or stress) fractures. These result from frequent repeated 
stresses on a bone leading to an eventual fatigue of the bone and 
fracture. This commonly occurs in athletes and military recruits. The 
lower limb is a common site for such fractures, mainly the metatarsals, 
fibula and neck of femur. 
4- Pathological fractures. These can occur secondary to bone lesions that 
weaken the bone e.g. bone tumours. A minor trauma can initiate the 
fracture and at times no trauma at all is necessary to induce it. 
1.2 NORMAL FRACTURE HEALING 
Fracture repair is a physiological process key to the restoration of bone integrity 
and function [6]. The reparative event in bone is unique in that it heals with bone 
without scarring. Two main types of fracture healing are known; indirect (or 
secondary) and direct (or primary). 
1.2.1 Indirect fracture healing 
This is the most common type of fracture healing and is characterised by the 
production of callus. It simulates both intramembranous and endochondral bone 
formation that is also seen in the embryo during skeletal development [7]. 
During endochondral ossification, mesenchymal stem cells (MSCs) differentiate 
into chondrocytes, which in turn lay down. a cartilaginous frame that becomes 
ossified to form bone. In contrast, during intramembranous ossification, bone is 
formed directly from mesenchymal tissue without the initial cartilaginous model [2]. 
This type of healing can be seen following non operative fracture management 
or following fixation of fractures using implants that allow micro motion at the 
fracture site (e.g. intramedullary nails) [8, 9]. Secondary fracture healing occurs 
over 3 overlapping stages; 1) the early inflammatory stage; 2) the repair stage 
(chondrogenic and osteogenic); and 3) the late remodelling stage [1] (Figure 1.1). 
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1.2.1.1 Inflammatory stage 
Immediately following an acute fracture, a haematoma is formed from the 
bleeding ends of bone and surrounding soft tissues and an acute inflammatory 
response is triggered. At the molecular level, this is a very complex and 
coordinated process which involves the release of multiple sets of molecules: 
pro-inflammatory cytokines, growth and differentiation factors, 
metalloproteinases and angiogenic factors [10]. The acute inflammatory 
response peaks in the first 24 hours and reaches an end within one week [11]. 
Phagocytic cells and macrophages in particular are attracted to the site of repair 
clearing away the debris and dead tissue that were formed as a result of the 
insult. This is in preparation for healthy granulation tissue formation, 
neovascularisation and attraction of MSCs to the site of repair [1]. 
The release of inflammatory mediators and cytokines mainly prostaglandins, 
tumour necrosis factor-a {TN F-a) , interleukin-1 (ll-1), interleukin-6· (ll-6), 
interleukin-11 (ll-11) and interleukin-18 (ll-18) promotes the recruitment of 
inflammatory cells and angiogenesis at the site of fracture [12]. Administration 
of non-steroidal anti-inflammatory drugs (NSAIDS) at this stage of the healing 
process can delay or even prevent fracture healing [13]. 
Bone needs osteogenic cells to regenerate and these are thought to be derived 
from the differentiation of MSCs residing in neighbouring BM, bone cortex, 
periosteum and adjacent soft tissue [14]. Bone marrow MSCs (BM MSCs) are 
highly proliferative stromal cells that are clonogenic and are capable of 
trilineage differentiation into bone, cartilage and fat. In addition to local 
. recruitment, it has also been suggested that MSCs are possibly systemically 
recruited via the circulation from sites distant to the fracture [15-17]. However, 
this is a contentious assertion and is not supported by other studies [18-20]. 
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Bone morphogenetic proteins (BMPs) are members of the transforming growth 
factor beta (TGF-I3) superfamily which consists of at least 34 members; they are 
key molecules involved in the induction of differentiation, growth, apoptosis and 
morphogenesis of different types of cells [21, 22]. BMPs 2 - 7, 9 and 14 are 
known to be responsible for MSC recruitment and osteoblastic differentiation 
during fracture healing [22, 23]. During the inflammatory stage, BMP-2 and 4 
seem to be the main players in recruitment of MSCs to the site of repair and 
later in the repair process; they promote the differentiation of MSCs into 
chondrocytes which form the cartilaginous soft callus. During the osteogenic 
phase of fracture healing BMP-7 together with other BMPs is highly expressed 
with an exclusive peak at day 14 and 21 of BMP-7 and BMP-8A respectively [22]. 
1.2.1.2 Repair stage 
During this stage of the fracture healing process a cartilaginous frame known as 
"soft callus" is formed by intramembranous bone formation which connects the 
fracture ends together hence provides temporary stability. Under the effect of 
BMPs, undifferentiated MSCs proliferate and differentiate into chondroblasts 
which in turn become chondrocytes [24]. These secrete type" collagen and 
proteoglycans which form the soft callus [23]. For fracture healing to continue, a 
blood supply needs to be established for the developing callus [25]. An initial 
phase of chondrocyte resorption and degradation is essential to allow for 
healthy vascularisation of the callus. This is followed by chondrocyte 
hypertrophy with the subsequent release of angiogenic growth factors including 
angiopoietins and a vascular endothelial growth factor (VEGF) [26]. Calcification 
of the extracellular matrix then takes place [27]. 
Concomitantly, healing by intramembranous bone formation takes place. MSCs 
from the surrounding periosteum undergo osteogenic differentiation producing 
the "hard callus" directly without the cartilaginous frame noted in endochondral 
bone formation [28]. 
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1.2.1.3 Remodelling stage 
During this stage, coordination between the resorption of callus by osteoclasts 
and the deposition of lamellar bone by osteoblasts coexists. Cytokines including 
IL-1 and TNF-a orchestrate this stage and at the same time, the expression of 
BMPs is considerably reduced [29]. 
Figure 1.1: Stages of secondary fracture healing 
A: Inflammatory stage, haematoma formation at the fracture site. B: Repair 
stage, soft callus is developing at the fracture ends and C: Remodelling stage, 
callus has been resorbed and bone is being gradually restored to its original 
shape. 
1.2.2 Direct fracture healing 
Direct (primary) fracture healing occurs in cortical bone, when there is almost 
absolute stability at the fracture site and minimal gapping of fracture ends (e.g. 
following rigid internal fixation of fractures with compression plates). In simple 
terms, osteoclasts working together in groups known as "cutting cones" cause 
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bone resorption, and these are followed by osteoblasts that lay down new bone. 
This process aims at restoring the functional unit of cortical bone known as the 
Haversian system or osteon [6]. Characteristically, there is no callus formation 
during this process and bone is healed "directly" by bone [30]. 
1.3 LONG BONE FRACTURE NONUNION 
Whereas fracture healing is a physiological process, and theoretically all bones 
are expected to heal, this scenario is far from true in orthopaedic practice. 
Fracture nonunion is a serious complication with severe implications on patients 
including prolonged pain, suffering and reduced mobility. Despite the 
advancement of fracture fixation, in some instances however fractures fail to 
heal. The incidence of long bone nonunions has been reported in the literature 
to range from 5-10% [31]. 
In order to tackle this serious complication, one has to pose some seemingly 
obvious questions; when can a fracture be considered as "healed"? Secondly, 
when can it be described as a "nonunion"? There is no consistent definition of 
fracture union and nonunion in the literature, but one can describe 2 types of 
fracture union, clinical and radiological. Clinical union is characterised by the 
absence of motion and I or tenderness at the fracture site upon application of 
physiological pressure on the fracture site (directly or indirectly e.g. by weight 
bearing). Radiological union is diagnosed when callus is found bridging the 
fracture site at least 3 out of 4 cortices on 2 different plain x-ray views [32]. The 
.,,' 
Food and Drug Administration (FDA), in 1988, defined nonunion as "a fracture 
that is over 9 months old and that has not shown radiographic signs of 
progression toward healing for 3 consecutive months" [33]. Delayed union lies 
in the "grey zone area" between the expected time to union and the 
development of an established nonunion. There is no delineating line between 
delayed and nonunion, and this can be a source of great misunderstanding and 
debate amongst treating physicians. Chronic or synovial pseudoarthrosis 
develops as an end stage of a longstanding nonunion [34]. 
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1.3.1 Risk factors 
Various risk factors are known to contribute to fracture nonunion. Some of these 
factors are related to the general health state of the patient whereas other 
factors are affected by the local fracture environment. 
1.3.1.1 General risk factors 
Factors like age, dietary insufficiency and diabetes can cause health problems 
of varying degrees of severity and that may contribute to the development of 
nonunion. In osteoporosis, there is reduction in healing with reported reduction 
in osteoblasts and reduced amounts of callus produced and hence the time to 
union maybe prolonged [35-37]. 
As already stated, age is also another important risk factor for nonunion. 
Fractures in children and young adults heal much quicker than older individuals. 
This is due to the increase in both the vascularity and number of osteoblasts in 
the children's periosteum [38]. The frequency of MSCs in human 8M aspirates 
has been reported to decline with age [39], which was subsequently confirmed 
in the laboratory where the current work was undertaken [40]. Furthermore, 
MSCs from older donors appear to be less proliferative [41] and less capable of 
osteogenic and chondrogenic differentiation [40J. 
Diabetes is a chronic disease known to cause neuropathy and vasculopathy. An 
association between diabetes and delayed fracture healing has been reported 
in the literature [42). Bone marrow mesenchymal stem cells (8M MSCs) from 
patients with type 2 diabetes appear to be functional so the deleterious effects 
of diabetic background on bone healing is likely to be related to vascular 
deficiency rather than MSC/osteoblast deficiency [43] . 
Smoking negatively affects fracture healing and this has been studied at the 
molecular level by investigating nicotine which is a prominent component of 
cigarette smoke. Nicotine was found to reduce osteoblast proliferation during 
fracture healing and cause vasoconstriction reducing tissue perfusion and 
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oxygenation [44]. Functional nicotinic receptors are present on MSCs therefore 
nicotine can also negatively affect cellular processes involving MSCs [45]. In 
both human and animal studies, nicotine reduced bone healing rates following 
long bone fractures [46, 47] and after spine fusion [48, 49]. 
Non steroidal anti-inflammatory drugs (NSAIDs) have long been used for pain 
relief. However, they reduce osteoblastic activity by the inhibition of 
prostaglandin synthesis [50]. A recent study from the laboratory in which this 
work was carried out has shown that MSC chondrogenesis in particular is 
affected by NSAIDs and this is related to the inhibition of cyclooxygenase-1 
(COX-1) activity and prostaglandin E2 (PGE2) synthesis [51]. In a study on 240 
mice by Murnaghan et al [52], they reported an increased volume of soft callus 
and cartilage together with a delay in bone formation in the group of mice on 
NSAIDs. In a retrospective study of patients with diaphyseal fractures of the 
femur, treated with intramedullary nailing, Giannoudis et al [50], reported a 
significant increase in nonunion with patients receiving NSAIDs, in particular 
those who received such treatment for over 4 weeks. 
Corticosteroids are an important class of drugs widely used systemically to treat 
,various disease conditions including autoimmune diseases (including 
rheumatoid arthritis, RA), systemic inflammatory disorders and cancers. The 
main untoward effects on bone include, delayed bone healing [53, 54], 
osteoporosis [55] and avascular necrosis of the femoral head [56]. 
Finally, excessive alcohol drinking and poor diet are risk factors for nonunion. 
Alcohol inhibits new bone formation and mineralization [57], as it has a 
negative effects on both MSCs {58] and endothelial cells [59]. During fracture 
repair, there is high demand for proteins, calcium, phosphorus and vitamin D, 
therefore a balanced diet is important to ensure sound healing [60]. 
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1.3.1.2 Local risk factors 
Local factors include the anatomical site of the fracture, degree of fracture 
comminution, severity of the trauma sustained, extent of soft tissue damage and 
periosteal stripping, the absence or presence of infection, and the vascular state 
of the affected limb or region (both pre and post injury) and finally, the 
adequacy and stability of fixation used for treatment [37]. 
The degree of bone comminution and displacement of the fracture ends are 
governed by the magnitude of the causative trauma and initial strength of the 
bone prior to injury. Periosteal stripping and soft tissue damage are more likely 
to occur with high energy accidents [61]. Therefore, more healing complications 
can be anticipated following high energy incidents. 
The vascular state of the affected limb and bone is of utmost importance for the 
healing process. Since healing requires an adequate blood supply any 
reduction in blood flow will have a negative effect on the fracture healing 
process. The blood supply to the bone maybe reduced acutely with bone 
breakage, or it may be part of a pre-existing chronic vascular insufficiency (e.g. 
diabetic ischemia) [62]. 
Mechanical stability at the fracture site affects the size and volume of callus 
produced. For secondary healing to occur, micro motion should be present at 
the fracture site, however, when this motion becomes excessive, this can be a 
contributing factor for the development of nonunion [8, 9]. 
Good bone to bone contact is another key factor in bone repair. The larger the 
gap between fracture ends, the less stable the fixation becomes and the more 
challenging it becomes for callus to bridge this gap. Soft tissue interposition and 
bone loss reduces bone contact and hence affects the healing process 
adversely [63, 64]. 
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Fractures occurring in cancellous bone heal in a shorter period of time 
compared to those occurring in cortical bone. This is attributed to the fact that 
cancellous bone is more vascular than the latter. Due to their proximity to 
cancellous bone, fractures in the metaphysial region of long bones heal quicker 
than those in the diaphysis [38, 65]. 
1.3.2 Epidemiology 
Tibial diaphyseal fractures are the most common type of long bone fractures 
encountered by the orthopaedic surgeon. On average, there are about 26 tibial 
diaphyseal fractures per 100,000 of the population per year [66]. The 
commonest cause of tibial diaphyseal fractures is road traffic accidents (RTA). 
Soccer is the second most common cause [67]. 
Fractures of the tibia maybe treated operatively or non-operatively. Babis et al 
[68], reported that out of 48 patients suffering from distal tibia fractures and 
treated with hybrid external fixation, 5 developed nonunions. Collinge et al [69], 
reported a 5% reoperation rate for distal tibia nonunions following internal 
fixation with minimally invasive plates. In a systematic review by Lam et al [70J, 
nonunion of the tibia following reamed intramedullary nails was reported to 
range from 7- 20%. These reports indicate that nonunion of the tibia remains a 
significant problem despite the different treatment modalities. 
Similarly, femoral shaft fractures usually result from high energy trauma and are 
associated with varying degrees of soft tissue damage [71]. Results of operative 
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treatment are far superior to non operative treatment and they allow early 
mobilization hence reduce complications such as pressure sores, muscle 
wasting and respiratory insufficiency [72]. However, femoral nonunions remain 
problematic with nonunion rates of 1.6% reported with biological plates [73], 
12% with external fixation [74] and 1.9% with unreamed intramedullary nailing [75]. 
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Fractures of the shaft of the humerus represent 20% of all humeral fractures 
and account for 1 % to 3% of all fractures [76J. Sarmiento et al [77J, reported 
nonunion in 3% of his series of 465 closed humerus fractures treated with 
functional bracing. McKee et al [78], reported a 3% nonunion rate following 
fixation with dynamic plates. 
Despite the enormous progress made during recent decades in the treatment of 
long bone fractures, fracture healing is still hindered by complications, nonunion 
being one of the most serious. Nonunion represent a particular challenge, and 
the difficulties surrounding its management are frequently under estimated [72]. 
1.3.3 Classifications of nonunion 
Broadly speaking, according to the presence or absence of infection, nonunions 
can be divided into infected and aseptic. Based on the amount of callus at the 
fracture site, aseptic nonunion is further classified into hypertrophic 
(hypervascular, viable or vital) and atrophic (avascular, nonviable, avital) [79]. 
Radiographically, hypertrophic nonunions are characterised by an abundance of 
callus around the fracture ends which fails to cross the fracture site and unite 
the bone (Figure 1.2). The presence of callus proves that the fracture ends are 
viable and well vascularised and that the patients' fracture healing response is 
not the reason behind the nonunion. However, there is an ongoing mechanical 
instability issue that is the underlying cause of nonunion. Patients suffering this 
type of nonunion will benefit from revision, of their fixation with more stable 
implants [80]. 
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Figure 1.2: (A) Anteroposterior and (8) lateral view radiographs of the 
distal femur fixed with an intramedullary nail showing signs of 
hypertrophic nonunion 
The arrows point at the hypertrophic nonunion site, note the excessive callus 
formation and the persistent fracture gap. 
On the other hand, atrophic nonunion is characterised by minimal or absent 
callus formation on x-ray. The fracture ends look avascular and osteopenic and 
in later stages may become sclerosed (Figure 1.3). This reflects an inadequacy 
of blood supply or an inadequacy of osteogenic cells reaching the fracture site. 
This can happen after high velocity injuries where a great deal of periosteal 
stripping and soft tissue damage has occurred. In atrophic nonunion, the 
fracture ends are nonviable or avascular and this makes treatment of such 
patients very challenging. The treating physician should aim at stimulating the 
bone to be more biologically active and to improve the general health condition 
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of the patient and local biology at the fracture site to ensure an adequate inflow 
of osteogenic cells, growth factors and blood supply to enhance fracture healing 
[80]. However, recently, it was shown that atrophic non unions do not lack 
vascularity but other molecular events may be responsible for the radiological 
features of inertia visualised on the radiographs [81] . 
Figure 1.3: (A) Anteroposterior and (8) lateral view radiographs of the 
femur shaft fixed with an intramedullary nail showing signs of atrophic 
nonunion 
The arrows point at the atrophic nonunion site, note the absence of callus 
formation and the persistent fracture gap. 
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1.3.4 The diamond concept 
Giannoudis et al [7], proposed that four equally important factors are desirable 
for a successful bone repair process: adequate mechanical stability, growth 
factors (osteoinductive agent), osteoconductive scaffolds (autologous, 
allogeneic or synthetic) and osteogenic cells. This approach, known as 'the 
diamond concept' has received great attention lately (Figure 1.4) [7]. 
When a treating physician is faced with a nonunion case, it is wise to investigate 
and to plan further treatment for that patient along the 4 routes emphasised by 
the diamond concept. This offers a systematic approach to the diagnosis and 
treatment of the case. Bearing the diamond concept in mind, together with the 
known risk factors of nonunion, a treatment plan maybe put forward to properly 
address the problem. 
The study of mechanical aspects and scaffolds as possible treatment options 
for nonunion are beyond the scope of this study, however in the following 
chapter, the roles of MSCs and BMPs will be discussed. 
Osteogenic 
Cells 
Osteoconductive 
Scaffolds 
Factors 
Figure 1.4: The Diamond Model of Bone Fracture Healing Interactions 
(Image adapted from Giannoudis et ai, 2007) [7]. 
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1.4 SUMMARY 
This chapter set out the basic biology of fracture repair at the cellular and 
molecular levels. It also described the biological basis for nonunion and 
touched on the cellular and mechanical factors contributing to this. The next 
chapter will cover current strategies for the augmentation of fracture repair, 
some deficiencies in the knowledge pertaining to this and then sets out a series 
of research questions to explore fracture repair. 
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CHAPTER 2 
BIOLOGICAL 
ENHANCEMENT OF 
FRACTURE HEALING 
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2.1 INTRODUCTION 
Atrophic fracture nonunion develops from "poor biology" at the fracture site. The 
fracture ends are biologically inactive and hence treatment should be geared 
towards biologically enhancing the fracture union. Using the four prerequisites 
for sound healing defined by the diamond concept, a need for osteogenic cells 
and growth factors appears to be essential for treatment of this condition. In this 
chapter, enhancement of fracture healing using MSCs and BMP-7 will be 
discussed. 
2.2 MESENCHYMAL STEM CELLS 
By definition, a human bone marrow MSC is a highly proliferative, non-
haematopoietic stromal cell capable of differentiating and forming tissue of 
mesenchymal origin; bone, cartilage, and fat (Figure 2.1). 
Bone 
Mesenchymal Stem Cell 
(JG)G)Q 
G)G)G)Q 
Cartilage 
000 
000 
Fat 
Figure 2.1: Schematic of the 3 main lineages that MSCs can differentiate 
to. 
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MSCs are regarded as reservoirs of regenerative cells with known tissue 
specific characteristics [82]. They are thought to have the ability to migrate and 
home to sites of injury and under specific signals, differentiate into cells of the 
appropriate connective tissue lineage. These signals maybe caused by tissue 
damage in conditions such as trauma, fracture, inflammation, necrosis and 
tumour [83]. 
Due to their proliferative capacity and ability to differentiate into tissues of the 
mesenchymal lineage, MSCs have attracted increasing attention in the field of 
musculoskeletal regenerative medicine. They have the potential to regenerate 
and produce tissues such as bone and cartilage and are capable of producing 
growth factors and cytokines that aid in the repair and regeneration processes 
[82]. Currently, multiple orthopaedic conditions exist that have no satisfactory 
solution, an important example of which is atrophic nonunion of bone following 
fractures. It is believed that MSCs may provide a more definitive answer for 
fracture repair by the local augmentation of MSC numbers at fracture sites. 
Numerous in vitro and in vivo studies have been carried out to better 
understand the biology of MSCs, including their phenotypic characterisation and 
methods for their enrichment [84, 85]. Clinical trials have also been carried out 
to study the potential use of MSCs in bone repair including fracture nonunion 
[86-88] . 
The idea that MSCs circulate in humans is contentious and has not been shown 
by all working in the field [20]. Given that most stromal tissues appear to have 
an MSC reservoir then the need for a circulating MSC pool is further questioned 
[89]. However, the fact that MSCs can engraft after their systemic infusion has 
been demonstrated after allogeneic hematopoietic stem cell transplantation [90] 
and following injury in animal models [91]. 
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2.2.1 The discovery of mesenchymal stem cells 
The history of the field goes back over 140 years with the original description of 
putative MSCs in 1867 by a German pathologist named Clonheim. He noticed 
that BM contained fibroblasts that appeared to be capable of forming collagen 
at distant sites of wound repair in animals [92]. 
The Russian born histologist, Alexander Maximow (1874 - 1928), developed 
the unitarian theory of hematopoiesis or origination of blood elements from a 
common precursor cell. He also stated that the stromal/connective tissue 
environment in the marrow controlled haematopoiesis, a highly contentious 
statement during his career, but now dogma. He was also first to develop in 
vitro cell culture technique [93]. By then BM fibroblasts or hematopoietic-
supporting stromal cells have not been called MSCs, since their differentiation 
to mesenchymal lineages had not yet been proven experimentally. 
In the 1970s, a Russian scientist Alexander Friedenstein and co-workers 
conducted further in vitro experiments studying the function of 8M fibroblasts. 
They plated whole BM in plastic culture dishes for about 4 hours. They then 
discarded the non adherent cells and culture expanded the remaining adherent 
ones. They noticed that the adherent cells remained quiescent for 2-4 days and 
then began rapid division to form colonies. The resultant colonies were 
fibroblastic in appearance and where capable of forming bone or cartilage when 
transplanted in diffusion chambers in Figure 2.2. It is from this work that the 
term colony forming unit fibroblast (CFU-F) arose [89, 94]. 
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Figure 2.2: Diffusion chamber experiments originally described by 
Friedenstein 
Image adopted from Friedenstein, 1987 [95]. A: CFU-F colonies grown in tissue 
culture flask. B: diffusion chamber experiments. 
The term mesenchymal stem cell was later coined by Arnold Caplan and 
colleagues who further expanded on a concept of multi-lineage differentiation of 
CFU-Fs [96] . Currently, the term MSC denotes a BM derived stromal cell that is 
highly proliferative and capable of undergoing trilineage differentiation into 
bone, cartilage and fat [97). However, there is still some uncertainty as to 
Whether MSCs can really be true stem cells. This is because their life-long self-
renewal capacity has not yet been demonstrated in vivo [98). Therefore, MSCs 
have also been designated as multipotential marrow stromal cells or simply 
marrow stromal cells by some investigators [98, 99). In 1999 Pittenger and 
colleagues [100] published a key article in stem cell research, cited over 9400 
times on Google Scholar at the time of writing, showing the amazing 
proliferative and clonogenic potential of BM MSCs. 
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While MSCs were originally defined in the 8M [92], populations of MSCs were 
later derived from virtually every site in the skeleton [82] including the synovial 
membrane [101], joint fat pad [102] and joint synovial fluid [103], the role of 
these different niches of MSCs in fracture repair is incompletely defined. 
2.2.2 Characteristics of MSCs 
There is no single marker that can identify MSCs in all the tissues; therefore a 
combination of several parameters is used to define these cells both in vitro and 
in vivo. These include cell surface phenotype, morphology and function. 
Morphologically, they appear as spindle-shaped fibroblastic cells in culture [92]. 
However, freshly-isolated cells have a more flattened morphology and long 
cytoplasmic projections [84]. Numerous authors have used flow cytometry to 
phenotype MSCs [84, 104] and multiple markers were proposed to characterise 
them [85]. 
To ensure clarity and to standardize the nomenclature, the Mesenchymal and 
Tissue Stem Cell Committee of the International Society for Cellular Therapy 
was convened and issued the following statement to define an MSC; "First, 
MSC must be plastic-adherent when maintained in standard culture conditions. 
Second, MSC must express CD105, CD73 and CD90, and Jack expression of 
CD45, CD34, CD14 or CD11 b, CD79a or CD19 and HLA-DR surface 
molecules. Third, MSC must differentiate to osteoblasts, adipocytes and 
chondroblasts in vitro" [105]. This definition remains the gold-standard for all 
researches currently working in the field. 
Flow cytometry is a valuable tool used to determine the surface molecules on 
MSCs and has been used by numerous researches to characterise MSC 
populations. CD271 molecule is a low affinity nerve growth factor receptor that 
speCifically selects for 8M CFU-Fs [106]. CD271-positive 8M stromal cells have 
the CD45-lIow phenotype and express "classic" MSC markers CD73, CD105 
and CD90, as previously shown in the laboratory in which this work was done 
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[84, 85]. Therefore, in addition to standard CFU-F assay for MSC quantification, 
these cells can be also enumerated using flow cytometry [85], which is much 
less time consuming (2-3 hours instead of 14 days for a simple CFU-F assay). 
Enumeration of BM MSCs in nonunion patients using parallel CFU-F and flow 
cytometry assays has not previously been reported. 
2.2.3 In vitro differentiation of MSCs 
Part of the definition of an MSC is its ability to form bone, cartilage and fat. 
Functional assays to test the trilineage ability of MSCs in vitro have been 
developed and optimized [100] and differentiation assays were used as a 
measure of their proliferative capacity. Adipogenic and chondrogenic 
differentiation assays are outside the scope of this work however it is worth 
mentioning briefly the rationale behind these assays. With regards to 
adipogenesis, it is commonly induced by chemical and biological compounds, 
primarily insulin, using densely-packed confluent MSCs. Chondrogenic 
differentiation assays are performed in tri-dimensional "pellets", to mimic 
chondrogenic condensations occurring in vivo and are induced by the addition 
of TGF-~3 [100]. 
Osteogenic differentiation of MSCs is commonly performed using confluent 
cultures exposed to a mixture of osteoinductive agents (dexamethasone, 
ascorbic acid and glycerophosphate). Cells begin to mineralise during the 
second week of culture, leading to the formation of functional osteoblasts by 
week 3 [100]. Osteogenic progression is m~asured using alkaline phosphatase 
(ALP) and calcium assays at week 2 and 3, respectively [100, 107]. Often 
osteogenic differentiation assay is also performed at c1onogenic level; this 
assay is called colony-forming unit-osteoblast (CFU-O). The only difference 
between CFU-F and CFU-O is the composition of media used (standard 
expansion media versus osteoinductive media). 
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As mentioned in the above sections, the CFU-F assay was originally described 
by Friedenstein et al [108]. This test highlights the ability of MSCs to form 
colonies and hence is used as an indirect measure of MSC proliferation. Cells 
are seeded at low densities in plates, fed for 2 weeks after which they are fixed 
with formaldehyde and then stained with crystal violet. In humans, each MSC 
forms one colony, whereas in mice or rats, an MSC is capable of forming more 
than one colony due to its ability to detach [109]. This assay has become 
"traditional" and is widely used in many researches due to its ease and its value. 
The number of colonies found per dish is equivalent to the number of MSCs 
plated at the start of the assay. The colonies maybe examined under the 
microscope to confirm their fibroblast like morphology. In the studies undertaken 
in this thesis, both CFU-F and CFU-O assays will be used to measure the 
number and osteogenic capacity of MSCs in health and nonunion. 
2.2.4 Clinical applications of MSCs 
Human mesenchymal stem cells (hMSCs) are a very attractive cell therapeutic 
as they can be isolated from patients with relative ease, capable of in vitro 
expansion, can theoretically be genetically engineered to produce target genes, 
safe in that they do not carry the risk of tumour fonnation (unless subjected to 
excess stress or expansion) and are physiologically present in injury sites as 
part of the healing process [110]. In contrast, embryonic stem cells can fonn 
teratomas following in vivo implantation in animal models [111]. 
The successful use of MSCs in bone repair applications has been described in 
several pioneering early proof of concept studies [112-114]. In 1989 Connolly et 
a\ [114], reported good callus fonnation in 9 out 10 patients with delayed union 
of the tibia after injection of 8M at the fracture site. In 1999 Horwitz et al [112], 
infused unmanipulated 8M intravenously into 3 patients suffering severe 
osteogenesis imperfecta and demonstrated improved bone histology together 
with an increase of total body mineral content with this treatment, however, this 
Work remains contentious. In 2001 Quarto et al [113], used MSCs loaded on 
hydroxyapatite scaffolds to treat large bone defects in 3 patients and reported 
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good healing within 6 to 6.5 months post surgery in defects that would have 
otherwise required 12 to 18 months to heal. Goel et al in 2005 [115], reported 
healing in 15 out of 20 patients with tibia nonunion after injection of BM at the 
site of nonunion. Pioneering studies on BM aspirate concentrate (BMAC) by 
Hernigou et al in 2005 [116], have shown that percutaneously implanted 
autologous BM MSCs can improve clinical outcomes. Despite this, the use of 
MSCs in orthopaedic surgery remains patchy because the biology of MSCs in 
vivo in health and following fracture is not well understood. There remains a 
lack of biological basis for surgeons to use these cells routinely and a great 
need to better understand their biology, particularly their response to growth 
factors and whether or not these cells could be systemically homing to fracture 
sites following injury. 
It is well established that bone, periosteum and BM contain osteogenic 
progenitors and MSCs that can be used to aid bone healing [117]. Iliac crest 
bone graft has long been used to enhance bone healing in cases of non unions 
and spinal fusions, but this was not without complications. Donor site morbidity 
in the form of chronic pain from the site of the graft has always haunted both 
surgeon and patient alike and is reported in literature to range from 15-39% of 
cases for up to 2 years post operatively [118-120]. 
BM aspiration commonly obtained from the iliac crest is a minimally invasive 
technique requiring less surgical expertise than the "classic" iliac crest bone 
graft. Its MSC content offers the osteoinductive properties that iliac crest bone 
graft offers without the complications that may arise from the donor site. It has 
been used by numerous authors to enhance fracture nonunion. Moreover, BM 
is injected percutaneously in the site of the nonunion therefore minimizing the 
local risks of a second open surgery to introduce the bone graft such as 
infection and excessive soft tissue damage [116, 121]. Revision surgery to 
introduce bone graft has been described by Boyd as "bone grafting is primarily 
a second wounding procedure, in which surgeon hopes that the response of the 
bOdy will be more favorable than the response following the original trauma" [121]. 
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As mentioned above, Hernigou in 2005 [116] aspirated 20cm3 of autologous 8M 
from both iliac crests, concentrated them with a 8M concentrator, then injected 
the concentrate into the nonunion site of patients with atrophic nonunions of the 
tibia. In his series 53 out of 60 patients united with this technique. He evaluated 
the number of 8M MSCs after concentration that were percutaneously injected 
into the nonunion site using a simple CFU-F assay and was able to prove that 
the volume of callus produced and the union rate were directly proportional to 
the amount of MSCs injected. He noted a reduction of MSC numbers in patients 
with comorbidities like diabetes and in smokers. This study showed that a 
minimum of 30,000 CFU-Fs were needed at the nonunion site for it to heal 
[116]. Even though MSCs are known to exist in 8M, they are very rare [18]. 
Seebach et al [122], examined 8M samples of 55 individuals divided into 4 
groups. The groups were comprised of 13 patients who were involved in poly 
trauma, 15 patients with only one fracture, 20 suffering atrophic nonunion and 7 
healthy volunteers. He found a significant increase in CFU-F numbers in 
patients with poly trauma as compared to those suffering nonunion and a 
Significant increase in colony density between the poly trauma and the mono 
fracture group in males [122]. 
Several animal models have shown that the use of MSCs in conjunction with 
scaffolds or growth factors is associated with good outcomes in an orthopaedic 
setting [98, 123]. In a recent review by Jones and Yang [98], the importance of 
developing an animal model that closely resembles the clinical setting was 
emphasized. Currently, the subcutaneous implant model (studied most 
commonly in the immunocompromised "nude~ mice) and the diffusion chamber 
one have their strong points and weaknesses. In the former model, bone 
resorption has been reported with inadequate mechanical forces applied to the 
implant together with possible contamination of the study implant with the host's 
tissues. In the latter model, contamination with host tissue is no longer an issue 
as the study samples are isolated in a sealed chamber but the lack of 
mechanical forces and stresses remains a concern [98]. 
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2.2.5 Circulation of MSCs 
The traditional concept for the putative role of MSCs in tissue homeostasis and 
repair comes from the haematological 8M stem cell model. In the latter model it 
is well established that CD34+ 8M haematopoietic' cells or their more 
differentiated daughter progeny cells (Le. precursors for lymphocytes, 
neutrophils and monocytes) are capable of circulating. Thus, circulating 
erythrocytes oxygenate the tissues and innate immune cells and lymphocytes 
likewise egress to their designated tissue environments and carry out effector 
functions. 
The validated model for adult stem cells emanating from this haematological 
model has also been applied to MSCs [96]. As reviewed by Prockop in 1997 
[92], sites of induced tissue injury appeared to accrue cells derived from the 
marrow in the tissue repair process. In the last couple of decades numerous 
studies have reported that MSCs circulate in health and disease [17, 19, 20, 
124, 125]. Obviously a better understanding of the putative mechanisms of 
systemic circulation of MSCs could be immensely important for local and 
systemic strategies aimed at novel approaches to bone repair and non unions . 
. Several studies have shown that systemically injected MSCs may in some 
cases have the capacity to home to sites of tissue injury, but the artificial 
introduction of MSCs into the blood does not prove that they circulate under 
physiological conditions [18]. 
Indeed the circulation of MSCs in the blood remains a highly contentious area of 
debate. Embryologically, mesenchyme arises before a circulation develops and 
its presence is a prerequisite for a circulatorY system [126]. In the last decade, 
large numbers of tissue resident MSCs have been shown at virtually every 
skeletal site [127] which suggests endogenous tissue specific MSC pools that 
challenges the need for a circulatory physiological MSC pool. Furthermore, 
most of the existing work on circulation MSCs has not used rigorous phenotypic 
criteria for MSCs [128] and there has been a lack of data showing that putative 
circulating MSCs are actually highly proliferative and multipotential. 
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From the biological perspective it is well known that rheumatoid arthritis (RA), is 
an erosive polyarthritis and one putative mechanism for jOint erosion in RA 
relates to the hypothesis that an abnormal circulating stromal progenitor cell is 
capable of carrying the erosive phenotype to multiple joints. Indeed this model 
has had some compelling support from a recent animal model (murine), which 
showed that transplanted human MSCs translocated from one flank to the other 
to effect cartilage destruction. RA synovial fibroblasts were thought to be the 
reason behind the spread of the disease from one joint to another in severe 
combined immune deficiency (SCID) mice [129, 130]. 
When rigorous phenotypic and functional criteria for MSCs have been applied 
several groups have failed to demonstrate evidence of MSCs in the circulation 
[128, 131]. Jones & McGonagle [89], found no evidence for an MSC population 
in health and noted that cells that morphologically resembled MSCs had 
functional properties of tissue macrophages. Likewise several other stUdies 
failed to show evidence for MSCs in the circulation [19, 20]. 
2.2.6 Reamer irrigator aspirator 
The association between the increase in intramedullary pressure during 
reaming or nail insertion and pulmonary complications is well documented in 
literature [132, 133]. Pape et al [134], found that reamer systems which offer 
irrigation and aspiration while reaming, reduce the harmful systemic effects of 
subsequent nailing of femurs in sheep. The Reamer Irrigator Aspirator (RIA) 
system by Synthes, is designed to reduce: both intramedullary pressure and 
thermal necrosis risk [135] during reaming as it irrigates the canal with saline 
during the process (Figure 2.3). In theory, this reduction of intramedullary 
pressure reduces the risk of fat embolism and pulmonary complications. 
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Figure 2.3: The RIA system 
The arrows point to the inflow (irrigation) and outflow (aspiration) of saline to 
irrigate the medulla during reaming. 
The RIA system was found to generate a generous quantity of bone as a 
byproduct of the reaming process. Researchers examined the resultant bone 
from reaming as well as waste liquid and found it rich in MSCs [136, 137]. The 
large amount of graft generated together with the high MSC content, has 
encouraged its use by various authors as a method for harvesting bone graft 
material. Additionally, the bone material obtained is very malleable due to the 
small fragment size and may be very useful for certain applications. This 
method of graft harvesting is minimally invasive and has less donor site 
morbidity when compared to the classical iliac crest bone graft and at the same 
time is of great efficacy [138-140]. Several reports in the literature exist 
discussing RIA as a satisfactory method of bone graft harvesting for the 
treatment of nonunions (Figure 2.4) [138, 141-144]. 
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Figure 2.4: RIA as a graft harvester 
A: An unused 750~m filter to be attached to the RIA system prior to reaming to 
collect bone graft. B: Emptying the collected bone graft from the filter after 
reaming. C: The final bone graft. 
Based on the concept that RIA reduces the intramedullary pressure and hence 
the incidence of fat embolism, it was hypothesized that MSCs would not be 
mechanically translocated into the deep and superficial venous systems after 
reaming with RIA, whereas this would be more likely to occur following 
conventional reaming . 
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2.3 BONE MORPHOGENETIC PROTEINS 
The discovery of BMPs can be traced back to the pioneering work of Urist in' 
1965 when he showed that ground up matrix from the BM was capable of 
inducing osteogenesis in ectopic tissues [145]. The BMPs are members of the 
TGF-(3 superfamily; they are known to induce differentiation, growth, apoptosis 
and morphogenesis of different types of cells [146]. BMPs represent almost one 
third of the TGF-(3 super family, with at least 34 members already described [22]. 
The important role of BMPs in a wide range of developmental processes is well 
known; including BMP induced differentiation of osteoblast progenitors and 
subsequent bone development in adults, skeletal development, and limb 
formation in embryos [147]. Osteoblasts, chondrocytes and MSCs produce 
BMPs during fracture repair which then trigger a series of events that promote 
the formation of bone and cartilage. On a cellular level, they stimulate 
chemotaxis, MSC proliferation and differentiation, angiogenesis, and synthesis 
of extracellular matrix [83]. 
It is worth noting that BMPs are key players in all 3 stages of fracture healing. 
During the initial inflammatory stage, BMP-2 and 4 seem to be the main players, 
their role progresses into the chondrogenic stage of the repair phase of fracture 
healing together with BMP-3b and BMP-6. During the osteogenic phase of 
fracture healing, BMP-7, together with other BMPs, is highly expressed, with a 
peak at day 14 and 21 of BMP-7 and BMP-8 (Figure 2.5) [22]. 
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Figure 2.5: Schematic summary of BMP expression patterns during 
fracture healing 
(The dashed line represents a difference of opinion amongst scientists in terms 
of the timing of expression.) Image modified from Dimitriou et ai, 2005 [148]. 
Initially, numerous animal trials were carried out to test the safety and efficacy 
of BMPs in induction of osteogenesis [149-151]. As the results were promising, 
on the 1 ih October 2001, the Food and Drug Administration (FDA) granted 
Stryker Biotech approval for its BMP-7 implant under a humanitarian device 
exemption (HOE). Randomized control trials have shown recombinant human 
BMP-7 to be associated with improved fracture repair [152, 153]. In a study by 
Moghaddam et ai, [154], BMP-7 has been used for the treatment of nonunions 
of femur, tibia and humerus, with a success rate of 82%. In these settings, the 
therapeutically administered BMP-7 is thought to recapitulate normal BMP-7 
activity in physiological fracture repair. 
The BMPs interact with type I (BMPR1A), and type II (BMPR1 B) receptors on 
the cell surface. Seven type I (ALK1 -7) and five type II receptors (T~RII , 
ACTRIIA, ACTRIIB, BMPRII, AMHRII) have been identified in humans [155]. 
The BMP signaling propagation is initiated by BMPs binding to high-affinity BMP 
serine-threonine kinase receptors that transduce signals through Smad and 
non-Smad signaling pathways. Phosphorylated SMADs form protein complexes 
and by nuclear translocation activate downstream genes [155]. Interestingly, 
previous studies showed that BMP signaling transduction is associated with 
other signaling pathways including Wnt and FGF signaling, an activity that is 
highly regulated by BMP antagonists [156] . 
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Antagonists of BMP such as Noggin (Nog), Cerberus (Cer1), CAN (Cerberus-
DAN), Follistatin, Gremlin (Grem1), Chordin (Chrd), Twisted gastrulation 
(Twsg1), and Crossveinless 2 (CV2) regulate BMP activity through direct 
receptor binding [157]. Both BMPs and BMP antagonists have been involved in 
bone development and angiogenesis. BMPs are able to strongly promote MSCs 
recruitment and differentiation into bone-forming osteoblasts which can facilitate 
effective bone regeneration in orthopedic applications [158]. 
2.4 BONE MARROW CONCENTRATORS AND MSC 
ENRICHMENT 
The iliac crest BM is a known source of MSCs and has been used to promote 
healing in nonunion cases [159]. In order to enrich for osteogenic progenitors or 
MSCs, commercial BM concentrator devices have been used. Usually, 30ml to 
60ml of bone marrow aspirate (BMA) from the iliac crest is obtained, centrifuged 
in a cell separator and concentrated to 3ml or 6ml of BM potentially enriched for 
MSCs. This bone marrow aspiration concentrate (BMAC), can then be injected 
into the site of nonunion to promote fracture healing . 
. As previously discussed, Heringou et al [116], reported union in 53 out of 60 
patients with tibia nonunion using this technique. They showed that the volume 
of mineralised callus generated at the nonunion site was proportional to the 
number of CFU-Fs in the BMAC. 
In a recent prospective clinical and laboratory study by Jager et al [160], 75 
patients with bone defects greater than 1 cm x 1 cm were recruited. Half of their 
defects were filled with autologous cancellous bone graft, and the other half was 
filled with either BMAC loaded onto hydroxyapatite granules or BMAC loaded 
onto a porcine collagen sponge. Samples from the BM before and after 
concentration were obtained and examined for the presence of MSCs with flow 
cytometry, CFU-F and CFU-O assays. They reported complete bone healing at 
17.3 weeks in the hydroxyapatite group compared to 22.4 weeks in the collagen 
group. They also reported up to 5.2 fold increase in CFU-F numbers post 
concentration. 
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The BM concentrator devices thus offer an alternative, minimally invasive 
strategy for fracture repair using MSCs compared to growth factors or the use of 
allogeneic culture expanded MSCs that can be procured commercially. As 
shown by Jager et al [160], they may be combined with a scaffold for superior 
results. 
2.5 SUMMARY AND AIMS 
As outlined above, there are several biological strategies to treat nonunion, 
some involve the use of BMPs and others entail the use of autologous MSCs. It 
remains unclear which method is likely to be most efficacious. Furthermore, the 
interaction between MSCs and BMPs in fracture repair is poorly defined and the 
whole question of how growth factors and MSCs might work in unison to 
optimise bone regeneration in vivo in man is not yet clear. 
Finally, the biology of MSCs in blood circulation in humans is not well 
understood. It is known that MSCs tend to be associated with fat globules in the 
marrow [85]. Consequently, it might be expected that MSCs would be released 
in situations where the risk of fat embolism existed. The phenomenon of fat 
embolism following reaming and or nailing of long bone fractures is well 
described in the literature with translocation of fat intravascularly by mechanical 
means [161,162]. 
Hypotheses to be tested 
This thesis sets to explore the following hypotheses: 
1- The numbers and/or proliferative capacity of iliac crest 8M MSCs in 
patients suffering nonunion are lower compared to patients who suffered 
long bone fractures and healed uneventfully. If this true, the injection of 
extra MSCs in nonunion sites may be beneficial to induce repair. 
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2- BMP-7 will increase the in vitro MSC potency in patients suffering long 
bone fracture nonunion in a dose-dependent manner. 
3- MSCs are present in the vascular system following reaming with RIA at a 
lower frequency than in BM and this is a~ biophysical process. If such a 
scenario were true then MSC numbers would be expected to be greater 
in the lower limb femoral venous blood compared to antecubital venous 
blood from the upper limb due to the trapping of MSCs in the pulmonary 
and peripheral capillary networks. 
To address these hypotheses, this study has the following aims: 
1- To enumerate iliac crest BM MSCs and osteoprogenitors in a group of 
patients with long bone fracture nonunion (nonunion group) in 
comparison to patients with previous long bone fractures that have 
healed without delay andl complications (union group) who were used as 
"controls". This was done using gold standard assays for MSCs (CFU-F) 
and osteoprogenitors (CFU-O) or flow cytometry. To evaluate MSC 
proliferative capacity by measuring the sizes of individual colonies and 
the numbers of cells per colony. 
2- To investigate the effect of BMP-7 on cultured MSCs from nonunion and 
union patients following osteogenic differentiation and measuring the 
levels of calcium produced. To investigate the effects of BMP-7 on non-
cultured MSCs from both nonunion and union patients, following 
osteoinduction and measuring the levels of calcium and the numbers and 
sizes of CFU-F colonies. 
3- To enumerate circulating MSCs in upper and lower limb venous blood of 
nonunion patients immediately following reaming of their sound femur 
with RIA for bone graft harvesting. To investigate the presence or 
absence of circulating MSCs in union patients being operated upon for 
metal work removal. Additionally, to compare the findings from those 2 
groups with findings from the peripheral venous blood of normal healthy 
control patients and with early RA patients. 
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CHAPTER 3 
MATERIALS AND METHODS 
LEEDS UNIVERSITY LIBRARY 
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3.1 BASIC REAGENTS 
Dulbecco's Modified Eagle's Medium (DMEM), Dulbecco's Phosphate Buffered 
Saline (PBS) (1X, without calcium and magnesium), Trypsin! 
ethylenediaminetetraacetic acid (EDT A) solution (0.OS%/0.02% EDTA), and 
Penicillin/Streptomycin solution (all from Invitrogen) were used for cell culture 
experiments. The following reagents and solutions were purchased from Sigma: 
acetic acid, trypan blue 0.4% wlv (both for counting), (3-glycerophosphate, 
ascorbic acid, alizarin red and dexamethasone (all in powder form to make up 
osteogenic media), and dimethyl sulfoxide (DMSO, for freezing). Tissue culture 
plastic, including 1Sml centrifuge tubes, SOml centrifuge tubes, 3Smm x 10mm 
dishes, and pipettes, was from Corning. Prolypropylen microtubes were from 
Trefflab (O.Sml and 1.Sml), pipette tips were from Gilson. Also, 2.0ml cryovials 
were from Alpha laboratories. Non-haematopoietic (NH) expansion media was 
from Miltenyi Biotec and fetal bovine serum (FBS) was from JRH Biosciences. 
3.2 PREPARATION OF RECOMBINANT HUMAN BMP-7 
Recombinant Human BMP-7 (Peprotech) in vials of SOOjJg BMP-7 was 
centrifuged using Eppendorf Centrifuge Model S810 for 1 minute at 6S0 rcf. 
Thereafter, BMP-7 was reconstituted in distilled water to a concentration of 
0.1 mg/ml (SOOjJg BMP-7 dissolved in Sml distilled water). A buffer containing 
carrier protein (0.1% bovine serum albumin,_BSA) was made by mixing 0.1g of 
BSA with 100ml PBS. This mixture was sterile filtered. Forty-five millilitres of the 
0.1 % BSA was added to the Sml of 0.1 mg/ml BMP-7 solution to make up 
10jJg/ml stock solution. One hundred microlitre aliquots of the resultant mixture 
was made (each aliquot contained 1jJg=1000 ng/ml BMP-7) and were frozen at 
-80°C and thawed immediately prior to use. 
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3.3 PREPARATION OF OSTEOGENIC MEDIA 
Osteogenic media was composed of DMEM, 10% FBS, 100lJM ascorbic-2 
phosphate (As2P), 10mM J3-glycerophosphate, and 100nM dexamethasone. To 
prepare stock solutions from powders, 2Smg of dexamethasone was dissolved 
in 1280lJI of 100% ethanol to form SOmM stock solution. This was further 
aliquoted in 10lJI volumes and stored in sterile vials at -20°C. Ten microliters of 
SOmM solution was added to 1 ml of NH medium to give a SOOlJM solution, this 
was aliquoted in 20lJI aliquots (1 :SOOO dilution needed for final media). To 
prepare a 200mM stock solution of As2P, 2.S7g was dissolved in SOml of water. 
This was aliquoted into 2S0lJI aliquots (1 :2000 dilution needed for final media). 
To prepare 2M stock solution of J32-glycerophosphate, 10g J32-
glycerophosphate was dissolved in 23ml of water (1 :200 dilution needed for 
final media). This solution was aliquoted into 1.2Sml aliquots and stored in 
sterile Eppendorf tubes in -20°C. 
Osteogenic media was prepared in SOOml DMEM bottles. Fifty milliliters of 
DMEM was decanted from a fresh bottle, then SOml of 10% FBS, five 20lJI 
aliquots of dexamethasone, two 1.2Sml aliquots of J32-glycerophosphate and 
one 2S0lJI aliquot of As2P were added. The media was sterile filtered and 
stored at -20°C. 
3.4 BONE MARROW SAMPLE COLLECTION 
Under general anaesthesia, with the patient supine, the iliac crest region was 
sterilized and draped according to regular operating standards. A 2mm stab 
incision was made over the anterior iliac crest. 8M was aspirated with a Stryker 
13G match-ground bevel tip introduction needle by the same surgeon 
(Professor Giannoudis) into a heparinised 10ml syringe (Figure 3.1). To reduce 
the dilution by peripheral blood, the needle's position was changed after each 
1 
4mls of aspirate obtained. Immediately. the aspirate was transferred to Sml 
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vacutainer tubes containing EDT A. All samples were collected from the Leeds 
General Infirmary (LGI) and transported at room temperature to Leeds Institute 
of Molecular Medicine (LlMM), within 1 hour of collection, and processing was 
initiated immediately. 
Figure 3.1: Iliac crest bone marrow aspiration technique 
Under anaesthesia and sterile conditions, 10ml of BM is aspirated while altering 
the aspiration site every 4ml to reduce the risk of blood contamination . 
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3.5 BLOOD SAMPLE COLLECTION 
Under sterile conditions and general anaesthesia 10ml of femoral venous blood 
from the limb ipsilateral to the surgical procedure was obtained (Figure 3.2). 
Matched 10ml of peripheral venous blood from the contralateral antecubital vein 
using a 10G needle was collected by routine venipuncture straight after the 
reaming of the sound femur with RIA for bone graft harvesting (Group I patients 
in the study of MSC circulation) or after induction of anaesthesia and before 
beginning of the operation in the non RIA patients (Group II in the study of MSC 
circulation) . Samples were transferred to a 5ml vacutainer tubes with EDTA and 
labelled accordingly. Samples were all harvested in the LGI operation theatres 
and were transferred to L1MM at room temperature where they were processed . 
Figure 3.2: Femoral vein aspiration from the femoral triangle 
42 
3.6 PROCESSING OF BLOOD SAMPLES 
In the tissue culture hood, blood was transferred into 50ml Falcon tube where it 
was diluted (1 :2) with sterile PBS. The diluted blood was then layered on top of 
equal amount of Lymphoprep solution (Figure 3.3) then centrifuged for 20 
minutes at 650 rcf with no brakes. The interface zone (Figure 3.4) containing 
the MNCs was collected with a sterile pastette and emptied into a clean 50ml 
Falcon tube. A second centrifugation was performed at 650rcf for 5 minutes 
(with brakes on). Cell pellet was then re-suspended in 1 ml of DMEM media. Cell 
counting was then performed as described earlier and cells were seeded in 
100mm dishes at a density of 107cells/dish, in 10ml of NH expansion media. 
Cultures were fed by the exchange of 5ml of NH media twice weekly. On day 
14, colonies were fixed with crystal violet as described in section 3.10 and then 
counted. 
3.7 MESENCHYMAL STEM CELL SEEDING 
Initially, 3001-11 of freshly harvested BM aspirate was seeded in 10ml of 
DMEM/10% FBS for 48 hours to allow plastic adherence of cells. After that, 
media was removed and cells were washed gently 2 to 3 times with 10mls of 
PBS to eliminate haematopoeitc cells. A 10ml volume of fresh NH media was 
then added to each dish. All dishes were kept in an incubator at 37°C, 5% CO2 
and were microscopically examined at regular intervals to monitor progress of 
cell growth and early detection of colonies. Cells were fed once weekly by half 
NH media exchange. 
3.8 CELL COUNTING 
The number and the viability of mononuclear cells (MNCs) following Iymphoprep 
isolation was evaluated by diluting the cells with 0.4% w/v trypan blue. For 
counting cells 1:2 or 1:10 dilutions were performed, depending on the number of 
cells. For 1:2 dilution 101-11 of cells were diluted with 101-11 of trypan blue, and for 
1:10 dilution 101-11 of cells were diluted with 90J,J1 of trypan blue. A volume of 101-11 
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of the resulting mixture was placed in the haemocytometer chamber. The 
number of trypan blue negative cells was counted in four large grid squares and 
the number of MNCs per 1 ml was determined by the formula: 
Number of cells in 4 large grid squares x 10000 x Dilution factor in trypan blue. 
Figure 3.3: Lymphoprep technique 
The diluted blood is layered on top of the Lymphoprep solution in the hood prior 
to centrifugation. 
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Figure 3.4: Lymphopreped sample (A) before (8) after centrifugation 
Arrow denotes the interface zone. 
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3.9 PATIENT COHORTS 
All studies in this work were approved by Leeds (East) Research Ethics 
Committee Project No: OR06n651 and Project No: 04/Q1206/107 (Appendix 1 
section 9.1). All study subjects were informed regarding to the purposes of the 
specific study and gave a written consent (Appendix 2 section 9.2). 
Patients with pathological fractures, renal or liver failure, neoplastic conditions, 
or receiving treatment for osteoporosis were excluded from this work. As it was 
not ethically permissible to recruit healthy control patients in the CFU-F and 
BMP-7 parts of this study, patients who previously suffered long bone fracture 
nonunion and united uneventfully (referred to as "union" group in this work) 
were considered controls. The "nonunion" group of patients in this study refer to 
patients who were suffering from atrophic long bone fracture nonunion. 
3.9.1 Patient cohorts for CFU-F study 
The hypothesis under investigation was that the total number and size of CFU-F 
colonies from the nonunion group were significantly lower in comparison to the 
union group. 
A total of 22 BM aspirate samples from 22 patients (13 females and 9 males) 
were recruited for this study, age ranged from 18 to 63 years, mean age of 40.1 
years and median age of 41.5 years. A summary of patient demographics can 
be seen in Table 3.1. The nonunion group was formed of 11 patients (5 females 
and 6 males), age range from 19 to 63, mean age of 40.5 and median age of 
43. The union group was formed of 11 patients (8 females and 3 males), age 
range from 18 to 56, mean age of 39.7 and median age of 41. The union group 
Was randomly selected from a group of patients that were admitted to have their 
metal work removed following union of the fracture. 
45 
Table 3.1: Basic characteristics of patients participated in nonunion 
versus union CFU-F study 
Sample 10 Gender Age Diagnosis 
TR014 male 31 Nonunion femur 
TR016 male 19 Nonunion femur 
TR019 female 50 Nonunion femur 
TR021 male 22 Nonunion femur 
TR024 female 43 Nonunion tibia 
TR027 male 33 Nonunion femur 
TR031 male 62 Nonunion tibia 
TR032 male 63 Nonunion femur 
TR038 female 58 Nonunion tibia 
TR039 female 44 Nonunion tibia 
TR053 female 21 Nonunion tibia 
TR018 female 44 Removal of metal work tibia 
TR022 female 46 Removal of metal work tibia 
TR023 female 41 Removal of metal work femur 
TR025 male 33 Removal of metal work femur 
TR033 female 39 Removal of metal work tibia 
TR035 female 42 Removal of metal work tibia 
TR042 female 46 Removal of metal work femur 
TR043 male 18 Removal of metal work tibia 
TR044 female 56· Removal of metal work tibia 
TR045 male 41 Removal of metal work femur 
TR046 female 31 Removal of metal work femur 
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3.9.2 Patient cohorts for enumeration of 8M MSCs using flow 
cytometry 
To validate the data from the CFU-F study in the nonunion and union groups, 
flow cytometry was used. A total of 17 patients were recruited, 7 nonunion and 
10 union. Mean age of nonunion group was 42 years, median age 44 years, 4 
females and 3 males. In the union group, mean age was 43 years, median 41.5 
years, 5 females and 3 males. Patients for this study were both gender and 
aged matched. A summary of patient demographics can be seen in Table 3.2. 
Table 3.2: Characteristics of patients participating in MSC enumeration by 
flow cytometry 
Sample 10 Gender Age Diagnosis 
TR001 male 50 Nonunion femur 
TR014 male 31 Nonunion femur 
TR016 male 19 Nonunion femur 
TR019 female 50 Nonunion femur 
TR024 female 43 Nonunion tibia 
TR038 female 58 Nonunion tibia 
TR039 female 44 Nonunion tibia 
TR020 male 47 Removal of metalwork tibia 
TR025 male 33 Removal of metalwork femur 
TR035 female 42 Removal of metal work tibia 
TR042 female 46 Removal of metal work femur 
TR044 female 56 Removal of metalwork tibia 
TR045 male 41 Removal of metal work femur 
TR046 female 31 Removal of metal work femur 
TR051 male 36 Removal of metalwork tibia 
TR052 female 60 Removal of metalwork tibia 
TR058 male 38 Removal of metalwork femur 
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3.9.3 Patient cohorts BMP-7 study 
The effect of BMP-7 on the calcium production of BM MSCs and the 
proliferation of CFU-F colonies from BM MSCs from union and nonunion 
patients was studied using both expanded and non-expanded (native) MSCs. A 
total of 14 patients participated in this study, 7 females and 7 males, age ranged 
from 21 to 63 years old, mean age of 46.1 years and median age of 44 years. 
Demographics of patients can be seen in Table 3.3. 
Three different study groups were formed based on the type of sample tested. 
- Group A, native BM MSCs obtained from patients suffering from long 
bone nonunion. This group was composed of 6 patients, 3 females and. 
3 males, age range from 22 to 63 years old, mean and median age of 
48.7 years and 51 years respectively. 
- Group B, experiments were carried out on cultured expanded BM MSCs 
obtained from patients suffering long bone nonunion. This group was 
composed of 3 patients, 2 females and 1 male. Age ranged from 44 
years to 63 years, mean age of 55 years and median age of 58 years. 
- Group C, culture expanded BM MSCs from long bone fracture union 
patients were studied. This group was comprised of 4 patients, 2 males 
and 2 females. Age ranged from 21 to 62, mean age of 42 years old and 
median age of 42.5 years old. 
In all 3 study groups, the effect of no BMP-7, 1 DOng BMP-7 and 300ng BMP-7 
on calcium production and CFU-F colony proliferation was tested. 
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Table 3.3: Demographics of patients participating in the study of effect of 
BMP-7 on MSC proliferation and differentiation 
Sample 10 Gender Age Diagnosis Group 
TR021 Male 22 Nonunion femur A 
TR024 Female 43 Nonunion tibia A 
TR031 Male 62 Nonunion tibia A 
TR032 Male 63 Nonunion femur A 
TR038 Female 58 Nonunion tibia A 
TR039 Female 44 Nonunion tibia A 
TR032 (EX*) Male 63 Nonunion femur B 
TR038 (EX*) Female 58 Nonunion tibia B 
TR039 (EX*) Female 44 Nonunion tibia B 
TR034 (EX*) Male 62 Removal of metal work tibia C 
TR035 (EX*) Female 42 Removal of metal work tibia C 
TR037 (EX*) Male 21 Removal of metal work tibia C 
TR043 (EX*) Male 43 Removal of metal work tibia C 
* culture expanded 
Table 3.4: Summary of the study groups for the effect of BMP-7 on MSCs 
(Age 
Group n Female Range) 
designation 
Group description 
: n Male Mean, 
, Median 
A 
Fresh BM MSCS from nonunion 
3:3 
(22 -63) 
patients 48.7,51 
B 
Expanded BM MSCs from nonunion 
1:2 
(44 - 63) 
patients 55,58 
Expanded BM MSCs from Union - (21 - 62) 
C patients with long bone fractures that 2:2 
united without healing complications 
42,42.5 
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3.9.4 Patient cohorts for the study of MSC circulation 
For this study, a total of 71 samples from 47 patients were tested. Four different 
study groups were formed (Table 3.5). 
Group I, 12 patients suffering long bone fracture nonunion and are 
undergoing reaming of the sound femur with RIA for bone graft harvesting 
together with revision of their initial fixation. Age ranged from 19 to 63, 
mean and median age was 40.5 years old, 5 females and 7 males. A total 
of 24 venous blood samples (10ml each of matched lower limb femoral 
(ll) and upper limb peripheral venous blood (Ul), Figure 3.5) were 
collected from this group straight after the reaming process as this is the 
peak time where fat embolism is known to occur. Individual patient 
characteristics for this study can be seen in Table 3.6. 
- Group II, 12 patients where recent or intra-operative skeletal trauma 
including reaming did not take place (i.e. cold cases). As it was not 
ethically permissible to recruit healthy controls, this group served as 
control. Age ranged from 18 to 67, mean age of 41.5 and median age of 
40, 5 females and 7 males (Table 3.7). A total of 24 samples (10ml of 
femoral venous blood and 10ml of peripheral venous blood) from each 
patient were collected after induction of anaesthesia and before 
commencement of surgery (to ensure no surgical skeletal trauma took 
place). In cases where limb surgery was proposed, the blood samples 
were collected from the contralateral injured side. 
- Group III, 11 patients diagnosed as early RA and not under any 
immunosuppressive treatment. This group were selected on the basis of 
recent work suggesting that circulating MSCs may have been capable of 
carrying the disease from joint to joint via the circulation [129, 130J, Age 
ranged from 37 to 77 years old, mean age of 56 and median age of 53,8 
females and 4 males (Table 3.8). Only 10ml of peripheral venous blood 
samples (no femoral venous blood samples) were collected from this 
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group during their visit to the outpatient department. Ideally, matched 
femoral venous blood should have been collected from these patients, but 
this is neither ethical nor practical. 
- Group IV, 12 healthy controls were recruited to further look for circulating 
MSCs in the peripheral blood circulation. Their age ranged from 24 to 51 
years old, mean age of 32 and median age of 32 years old, 4 females and 
8 males. As was the case for Group III, only 10ml of peripheral venous 
blood was collected and no femoral blood samples obtained. Basic 
characteristics are shown in Table 3.9. 
Table 3.5: Study Groups for the circulation of MSCs in the blood 
(Age 
n 
Group 
Group description Female: 
Range) Samples 
Designation Mean, collected 
nMale 
Median 
Long bone fracture nonunion (19 - 63) 
I undergoing femoral reaming 5:7 LL,PB 
with RIA 
40.5,40.5 
Patients undergoing various (18-67) 
II surgical "cold" orthopaedic 5:7 LL, PB 
procedures 
41.5,40.5 
Early RA and not under any (37 -77) 
III immunosuppressive 7:4 PB 
treatment 
56,53 
IV Healthy controls 4:8 
(24 - 51) 
PB 
32,32 
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Figure 3.5: Venipuncture sites 
A: contralateral mediancubital vein. 8: ipsilateral femoral vein (image modified 
from Giannoudis et ai, 2010) [163}. 
Table 3.6: Basic characteristics of Group I patients participated in the 
MSC circulation study . 
Sample 10 Gender Age Diagnosis 
TR016 Male 19 Nonunion femur 
TR019 Female 50 Nonunion femur 
TR021 Male 22 Nonunion femur 
TR024 Female 43 Nonunion tibia 
TR027 Male 33 Nonunion femur 
TR028 Male 33 ~ Nonunion femur 
TR031 . Male 62 Nonunion tibia 
TR032 Male 63 Nonunion femur 
TR038 Female 58 Nonunion tibia 
TR039 Female 44 Nonunion tibia 
TR040 Male 38 Nonunion tibia 
TR053 Female 21 Nonunion tibia 
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Table 3.7: Basic characteristics of patients from Group II patients 
participated in the MSC circulation study 
Sample 10 Gender Age Diagnosis 
TR029 Female 39 Sacroilitis for sacroiliac screws 
TR030 Male 67 Removal of metal work ankle 
TR034 Male 62 Removal of metal work tibia 
TR036 Female 42 Sacroilitis for sacroiliac screws 
TR037 Male 21 Removal of metal work tibia 
TR041 Male 38 Osteomyletis tibia for debridement 
TR047 Female 46 Cocydena for local injection 
TR054 Male 18 Osteomyletis tibia for debridement 
TR065 Female 56 Sacroilitis for sacroiliac screws 
TR077 Male 41 Meniscal tear of knee for arthroscopy 
TR078 Female 31 Sacroilitis for sacroiliac screws 
TR080 Male 38 Osteomyletis tibia for debridement 
Table 3.8: Basic characteristics of early RA patients participated in the 
study 
Sample CRP* ESR* 
plasma 
Gender Age 
10 viscosity* 
TR066 Female 77 <5.0 11 1.53 
TR067 Female 37 27 39 N/A 
TR068 Female 41 <5.0 12 N/A 
TR069 Female 59 34 42 N/A 
TR070 Male 70 <5.0 10 N/A 
TR071 Male 54 28 N/A 1.73 
TR072 Female 51 <5.0 N/A 1.74 
TR073 Male 49 56 N/A 2.03 
TR074 Female 73 54 9 N/A 
TR075 Male 53 <5.0 9 N/A 
TR076 Female 49 <5.0 9 N/A 
*inflammatory markers used to assess the degree of inflammation in RA patients 
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Table 3.9: Basic characteristics of healthy control patients participated in 
the study 
Sample 10 Gender Age 
TR048 Female 24 
TR049 Female 30 
TR050 Male 46 
TR055 Male 37 
TR056 Female 35 
TR057 Male 32 
TR059 Male 31 
TR060 Male 37 
TR061 Male 40 
TR062 Male 27 
TR063 Male 51 
TR064 Female 27 
3.10 CFU·F ASSAY 
All CFU-F assays on BM aspirates were performed from freshly harvested 
samples obtained as outlined in section 3.4. A volume of 3001J1 of BM sample 
was initially seeded in 100mm diameter petri-dish with 10ml of DMEM/1 0% FBS 
for 48 hours to allow for plastic adherence of cells. Thereafter, media was 
removed and cells were washed gently 2 to 3 times with 10ml of PBS to 
eliminate haematopoietic cells. A 10ml volume of fresh NH media was then 
added to each dish. All dishes were kept in an incubator at 37°C, 5% C02 and 
were microscopically examined at regular intervals, to monitor progress of cell 
growth and early detection of colonies. Cells were fed once weekly by half NH 
media exchange. 
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The experiment was ended at day 14. Media was removed; cells were gently 
washed twice with 10ml PBS after which 5ml of 3.7% formaldehyde was added 
for 15 minutes to each dish to fix the cells. Excess formaldehyde was poured off 
and 5ml of 1 % Crystal Violet stain (w/v) was added for another 15 minutes. 
Dishes were washed extensively with tap water and left to dry. Dishes were 
then scanned at 360 dpi (Epson Perfection 3590 Photo Scanner) with images 
processed using ArcSoft Photostudio version 5. 
3.11 CFU-O ASSAY 
Colony forming unit osteoblast (CFU-O) assay was performed as a measure of 
osteogenesis of individual colonies. Three hundred microliters of fresh BM 
aspirate was plated into a 100mm diameter petri-dish with 10ml of DMEM/1 0% 
FBS and incubated at 37°C, 5% CO2 for 48 hours to allow plastic adherence of 
cells. Two 10ml PBS washes were done to remove red cells, then 10ml of 
osteogenic media was added to each dish. Half the volume of osteogenic media 
was exchanged once weekly for cell feeding. On day 14, ALP staining (see 
below) of the adherent colonies was performed. 
For ALP staining assay, citrate working solution was first made up by the 
addition of 2ml citrate concentrated solution (Sigma) to 98ml of deionised water. 
To prepare the fixative, 20ml of citrate working solution was added to 30ml of 
acetone ('NVR International). Fast blue solution was prepared by dissolving the 
contents of one capsule of fast blue RR sal~ (Sigma) in 48ml of distilled water, 
2ml of Napthol AS-MX phosphate alkaline solution mix (Sigma) was then 
added, the mixture (called fast blue solution) was covered with foil to protect it 
from light. Using a Pasteur pipette, the osteogenic media was removed from the 
dishes. Cells were washed twice with 10ml of PBS after which 2ml of fixative 
Was added gently and left for 30 seconds. Cells were then washed with 
deionized water. A volume of 5ml of fast blue solution was added to each dish 
and incubated for 30 minutes in the dark at RT. Cells were then washed twice 
with 10ml of deionized water. Then, 2ml of Mayers Haematoxylin (Sigma) was 
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next added for 10 minutes. Finally, cells were washed twice with 10ml of 
deionized water and left to dry. Blue colouring of colonies occurred with ALP 
activity which indicates osteogenesis. Samples were left to dry, then scoring 
and scanning was performed as described above. 
3.12 PERFORMING PROLIFERATION AND OSTEOBLASTIC 
DIFFERENTIATION ASSAYS IN THE PRESENCE OF 
BMP-7 (FRESH MSCS. GROUP A) 
The overwhelming majority of MSC based research is carried out on culture 
expanded MSCs. However, the functional assessment of freshly isolated MSCs 
prior to prolonged culture manipulation may be much more representative of 
What is going on in vivo. For this arm of the study, 3001-11 of fresh iliac crest BM 
was seeded in 6 dishes (duplicates) in 10ml of DMEM/1 0% FBS and incubated 
at 37°C, 5% CO2 for the first 48 hours to allow for plastic adherence. Media was 
then removed, and cells were gently washed 2-3 times with 10ml of PBS to 
eliminate non adherent haematopoeitc cells. Ten millilitres of NH media were 
added to each dish and supplemented with the relevant BMP-7 dose according 
to the study group. On the ih day from the change of media to NH, cells were 
fed by 5ml media change and an additional dose of BMP-7 was added again 
according to the study group. A week later (day 14), experiments were stopped 
for CFU-F assay. 
3.13 EVALUATION OF COLONY SIZES AND SURFACE 
AREAS USING A GRID 
Using Microsoft Office Word 2007, four 150 x 150mm grids graticuled into 10 x 
10mm; 7.5 x 7.5mm; 5 x 5mm and 2.5 x 2.5mm were designed Figure 3.6. The 
surface area of each colony was measured against these grids. The total colony 
count and the colony count per group size was noted. The surface area of each 
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colony was estimated to be equivalent to the surface area of the best fitted grid 
square. Using Microsoft Office Excel, the total surface area of all colonies was 
calculated and an average colony surface area was estimated (total surface 
area of all colonies/colony count). 
Figure 3.6: Example of a grid used for colony scoring (not to original size) 
Four grids were made graticuled into 10 x 10mm; 7.5 x 7.5mm; 5 x 5mm and 
2.5 x 2.5mm. Dishes were placed on top of these grids and colonies were 
scored. 
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3.14 MEASUREMENTS OF CELL GROWTH 
CHARACTERISTICS AND POPULATION DOUBLING 
TIME IN OSTEOGENIC CONDITIONS 
In these experiments 300JJI of fresh BM aspirate was plated into a 100mm 
diameter petri-dish with 10ml of DMEM/1 0% FBS and incubated for 48 hours to 
allow plastic adherence of cells. After that, red cells were removed with two 
10ml PBS washes. The remaining cells were left to grow in 10ml of osteogenic 
media for 14 days with half the media volume was exchanged once weekly for 
cell feeding. On day 14, cells were trypsinised and then counted using trypan 
blue staining and haemocytometer. To trypsinise cells, two 5ml washes with 5ml 
PBS were initially performed, after which 3ml of trypsin was added to facilitate 
cell lifting and the plates were incubated for 2-3 minutes at 37°C. To deactivate 
the trypsin, 5ml of DMEM/10% FBS was added to each plate. Cells were 
examined microscopically to ensure complete cell lifting has occurred. If 
remaining adherent cells were noted, mechanical lifting was done with the use 
of a cell scrapper. The cell suspension was transferred to a falcon tube and 
then centrifuged for 5 minutes at 650rcf. The cell pellet was resuspended in 
800JJI of DMEM/10% FBS and cells were counted as described earlier. 
Population doublings (PDs) achieved by MSCs were calculated using the 
formula: 
PDs= log2 (number of cells at trypsinisation 1 CFU-O per dish). PO rate (on day 
14) was calculated as PDs/14. 
Population doubling time (PDT) at day 14 was also calculated as follows: 
• 
PDT= (14 log2) 1 log number of cells at trypsinisation -log CFU-O per dish 
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3.15 EXPANSION OF MSCS FOR GROUPS BAND C IN 
BMP-7 EXPERIMENTS 
In these experiments 300IJI of fresh BM aspirate was plated into one 100mm 
diameter petri-dish with 10ml of DMEM/1 0% FBS and incubated for 48 hours to 
allow plastic adherence of cells. After that, red cells were removed with two 
10ml PBS washes. The remaining cells were left to grow in 10ml of NH media 
until confluence. In the meantime, half the media volume was exchanged twice 
weekly for cell feeding. Dishes were examined regularly under the microscope 
to monitor cell growth. Once confluent, pO cells were trypsinised and then 
counted using trypan blue staining and haemocytometer as described in section 3.14. 
3.16 THE STUDY OF THE EFFECT OF BMP-7 ON THE 
OSTEOGENIC DIFFERENTIATION OF EXPANDED 
MSCS 
MSCs cultured to passage 3 from the same patient were counted and seeded in 
duplicate dishes in osteogenic media as described in section 3.11. Three 
groups were established: no BMP-7, 100ng/ml BMP-7 and 300ng/ml BMP-7. 
BMP-7 was added accordingly on the time of seeding. Cells were fed by half 
media change after one week during which another dose of BMP-7 was added 
according to the group. On day 14, the osteogenic differentiation process was 
ended and a colorimetric calcium production assay was performed. 
3.17 COLORIMETRIC CALCIUM PRODUCTION ASSAY 
Fully functional osteoblasts produce calcium as their final product; this was 
Used as measure of osteoblastic differentiation. On day 14, the osteogenic 
medium was removed, and the cells were washed twice with 10ml of calcium 
free PBS. To extract the calcium bound to cells, 3ml of 0.5N Hcl was added in 
each dish and incubated at room temperature (RT) for 5 minutes. With a cell 
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scraper, cells were scraped off the surface of the dishes. This suspension was 
then transferred to two 1.5ml Eppendorf tubes with a 5ml syringe and needle. 
Cells were allowed to mix in the cold room at 4°C for 4 hours using a rotator, 
and were subsequently stored at -20°C. 
The amount of calcium produced by osteoblasts was quantified based on a 
direct colorimetric method, Cresolphtalein complexone (CPC) using Sentinel 
Diagnostics' calcium kit. The kit was composed of 3 reagents: reagent 1, 
reagent 2 and standard. Reagent 1 was 2-aminoethanol buffer (MEA), reagent 
2 was CPC and Calcium standard was supplied as 10 mg/dL(100l-lg/ml) 
solution. A round bottom 96 well plate was labelled as dilution plate then 501-11 of 
0.5N Hcl was added from wells 81-H1, 82- H2, 83 - H3 to prepare dilutions of 
calcium standard (Figure 3.7 A). Then .. 501-11 of standard calcium solution was 
added from well A1 - A3 and 81 - 83 (Figure 3.78). Using a multichannel 
pipette, serial dilution of the standard calcium solution was performed from 81-
83 to H1-H3 (501-11 of the contents of each well was removed, then added to the 
following row and this process was repeated till row H. Figure 3.7C shows the 
calcium concentrations in each well. 
Working reagent solution was prepared by mixing 15ml of reagent 1 with 6ml of 
reagent 2 (5:2). A flat bottom 96 well plate was then labelled as "reading plate". 
Two hundred microlitres of the working solution was added to each well in the 
reading plate. Four microlitres of calcium standard was transferred from the 
mixing plate to the corresponding well of the reading plate. Three, 41-11 aliquots 
(triplicates), of the sample to be tested was then transferred to the reading plate 
(Figure 3.70). The amount of calcium per well was measured photometrically 
using a 570nm filter on a Mithras L8 940. Standard calcium curves where then 
plotted using Microsoft Excel 2007 and an equation was produced; this was 
later used to measure the amount of calcium per well. 
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Figure 3.7: Calcium assay procedure 
A - Dilution plate, Step 1, preparing to dilute calcium standard. B - Dilution 
plate, Step 2, adding calcium standard. C - Dilution plate, Step 3, making 
dilutions of calcium standard. D - Reading plate, Step 4, adding samples and 
standards to working solution. 
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3.18 MONONUCLEAR CELL FREEZING 
To freeze cells, freezing medium containing 10% DMSO, 4S% DMEM and 4S% 
FBS was used. A solution containing 10% DMSO, 4S% DMEM, and 4S% FBS 
was prepared in a special falcon tube which was kept on ice. A volume of 1 ml ~f 
the freezing media was added to the cell pellet (average 107 MNCs/ml) and 
thoroughly mixed. The content of the tube was transferred into a cryovial, which 
was placed in a cool freezing container (Nalgene containing isopropanol) for 1-2 
days at -80 °C. Finally, the tubes were transferred to the Liquid Nitrogen (LN2) 
tanks for long term storage. MNC stocks were kept in LN2 facility for future use. 
3.19 REVIVING FROZEN CELLS FOR FLOW CYTOMETRY 
Deoxyribonucleate S'-oligonucleotido-hydrolase (DNAse), Sigma, was dissolved 
in 2.7Sml of PBS and frozen at -20°C in 40ul aliquots. Forty microliters of 
DNAse was added to 20ml of thawing media (DMEM /10% FBS). DNAse was 
added to defrosting media to avoid cell clumping/cell loss during reviving 
process. 
Samples were held in the water bath at 37°C to defrost for about one minute. 
The defrosted sample was then emptied into a SOml Falcon tube. Thawing 
media (DMEM/10% FCS) containing DNAse was added to the sample very 
sloWly (drop by drop) using a pastette until 20ml of volume was reached. The 
'. 
empty storage vial was rinsed with thawing media containing DNAse and its 
content emptied into the Falcon tube. A 70-:-micron cell strainer was sometimes 
Used to filter the solution if clumps developed. The sample was centrifuged for 
10 minutes at 6S0 rcf. The supernatant discarded and the pellet slowly re-
sUspended in 2ml thawing media. A standard trypan blue cell count was 
performed and cell number calculated using the aforementioned formula. 
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3.20 FLOW CYTOMETRY 
Flow cytometry was performed to independently validate CFU-F data using a 
two colour Becton Dickinson FACScan. Jones et al [85], showed that flow 
cytometry for the CD451owCD271 + cell population is a reliable method for 
detection, enumeration and phenotypic characterisation of BM MSCs in both 
healthy and diseased individuals. 
For flow cytometry experiments, BM aspirates were undergone mononuclear 
cell (MNC) fractionation using (Lymphoprep). MNCs were frozen at 107cells/vial 
and stored in LN2. Prior to flow cytometry, MNC were de-frosted, as described 
above and stained with appropriate antibodies. Antibodies and isotope controls 
used for flow cytometry are shown in Table 3.10 and Table 3.11. Staining was 
performed as follows. In a 96 well round bottom plate, cells were added into 
well A 1 and A2. The plate was spun down for 1 minute at 650 rcf. Supernatant 
from both wells was discarded. Remaining pellet in well A 1 was stained with the 
primary conjugated antibodies, wereas pellet in well A2 (control) was stained 
with isotype controls. Plate was kept in the fridge for 20 minutes at 4°C. Cells 
were then washed with 150ul of Facsflow (BD) then spun again for 10 seconds 
at 650 ref. Supernatant was discarded. Two 5ml polystyrene round bottom 
tubes (BD) were placed in ice and filled with 0.9ml of Facsflow each. One 
hundred microliters of Facsflow was added in wells A 1 and A2 and contents 
pipetted into a FACS tube which was labeled accordingly. 
As mentioned above, cells were stained with CD45-FITC and CD271-PE 
(LNGFR) conjugated antibodies to identifiCD45lowCD271+ cell population. 7-
AAD staining was incorporated to exclude dead/dying cells. Data were acquired 
USing BD FACScan equipped with CellQuest software version 3.1 (BD 
Biosciences). Gating strategy for the enumeration of CD45,owCD271 + cells is 
Shown on Figure 3.B. 
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Figure 3.8: Gating strategy for MSC enumeration by flow cytometry 
A - cell debris are excluded based on size. B - dead cells excluded based on 7-
AAO staining. 7-AAO+ cells are dead/dying, 7-AAO- cells are live. C -
C0451owC0271 + cell population is identified as a tight cluster (R2) and its 
frequency is calculated as a percentage of live cells (R3, haematopoietic cells 
not measured). 
Table 3.10: List of antibodies used for flow cytometry 
Product 
Specificity Conjugate Isotype Clone Manufacturer 
Number 
C045 FITC 
IgG1, 
T29/33 F0861 Oako 
Kappa 
C0271 PE 
IgG1, 
C40-1457 557196 BO 
Kappa 
Table 3.11: List of isotype controls used for flow cytometry 
Product 
Conjugate Isotype Clone Manufacturer 
Number 
FllC IgG1 , Kappa MOPC-31C 550616 BO 
PE IgG1 , Kappa B56 556027 BO 
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3.21 STATISTICAL ANALYSES 
All calculations were done using GraphPad Prism 5 software version 5.04. 
Normality testing was carried using Shapiro-Wilk test to determine whether the 
data were parametric or nonparametric. Nonparametric statistics was used as 
data was found to be non parametric. Non-matched and donor-matched data 
were compared using the unpaired (Mann-Whitney) and paired (Wilcoxon) 
nonparametric tests, respectively. Data were expressed as means (standard 
deviation) or median (range) as appropriate. The cut-off value for significance 
was p=0.05. 
For studies to explore the circulation of MSCs in the blood in health, 
orthopaedic procedures and early (section 6.1), statistics were carried out using 
SPSS 15 (SPSS Inc) software, the odds ratio test was carried to compare 
findings of MSCs in the upper limb venous blood (UL) and the lower limb 
venous blood (LL). An assumption was made that samples are indepelndent 
based on the extreme rarity of MSC colonies in the blood. The cut-off value for 
significance was p=0.05. 
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CHAPTER 4 
RESULTS OF CFU-F STUDY 
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4.1 COMPARISON BETWEEN THE NUMBERS OF MSCS 
AND OSTEOPROGENITORS IN BM ASPIRATES IN 
NONUNION AND UNION PATIENTS 
The hypothesis under investigation was that the total number and size of CFU-F 
colonies from nonunion patients will be significantly lower in comparison to long 
bone fracture union patients. A total of 22 patients were recruited for this study 
11 in each study group. 
A volume of 10ml of BM from the anterior iliac crest was aspirated from these 
individuals according to protocol described in section 3.40. A comparison 
between BM CFU-F and BM CFU-O colony numbers and sizes between these 
2 groups was performed. Both assays were carried out in a standardised way 
(see sections 3.10 and 3.11 respectively) in duplicate or triplicate dishes and 
experiments were ended on day 14. Colony surface areas were worked out 
using the grid described earlier (section 3.13). 
4.1.1 CFU-F assay validation 
CFU-F assay was performed in duplicate or triplicate dishes and it was 
important to assess the technical variability between the dishes before 
evaluating differences between patient groups. Using Microsoft Excel 2007, the 
mean, standard deviation (SO) and coefficient of variation (CV) was calculated 
for a group of union patients and an average of 23.6% variability between 
dishes was noted (Table 4.1). . 
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Table 4.1: Variability between CFU-F assay duplicates and triplicates in 
union group 
Sample ID Colonies per dish Mean SD CV* 
Dish 1 Dish 2 Dish 3 
TR018 15 18 16.5 2.1 12.9 
TR023 6 6 6.0 0.0 0.0 
TR033 5 6 5.5 0.7 12.9 
TR035 17 8 12.5 6.4 50.9 
TR025 8 4 7 6.3 2.1 32.9 
TR043 19 22 16 19.0 3.0 15.8 
TR044 6 5 8 6.3 1.5 24.1 
TR022 17 35 15 22.3 11.0 49.3 
TR042 32 30 30 30.7 1.2 3.8 
TR045 10 15 18 14.3 4.0 28.2 
TR046 4 7 5 5.3 1.5 28.6 
Average 13.2 3.0 23.6 
* CV is calculated as (SD/Mean)x100% 
4.1.2 Differences in CFU-F numbers between union and nonunion 
patient groups 
The total CFU-F colonies in the nonunion group were compared to the union 
(Figure 4.1A). Statistical analYSis performed using the Mann Whitney Test, 
showed that the total CFU-F number in the nonunion group was significantly 
higher than in the union group (median values 29 and 12.5 colonies 
respectively, p=0.0488). This was unexpected since it contradicted the initial 
hypothesis. More donor-to-donor variability was noticed in the nonunion group 
(range 3 to 139 colonies) compared to the union (range 5 to 31 colonies), but 
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this could not be simply explained from patient's demographics data, since both 
groups were age-matched. 
It was noted however, that the two groups were not completely gender-
matched, female: male ratio was 5:6 in nonunion group and 8:3 in the union 
group. Therefore, a comparison was between the CFU-F numbers in female 
and male patients in the union group was carried out and no significant 
differences were found (12 and 16 colonies for females and males, respectively, 
p=O.3758). It was therefore concluded that the differences between nonunion 
and union groups could not be attributed to gender composition of these two 
groups. 
Statistical analysis revealed that the total CFU-O numbers in the nonunion and 
union groups were not significantly different (p=O.5952). This was contrasting 
CFU-F data and suggested that the increase of total CFU-F in the nonunion 
group was not due to increased numbers of osteoprogenitors. To explore these 
findings further, colonies were scored using the grid mentioned earlier (section 
3.13). The results for CFU-F colonies are shown on Figure 4.2 and Figure 4.4. 
A B 
Total CFU-F Count Total CFU-O Count 
p=O.0488 p=O.5952 
150 150 
• 
=-100 ~1oo 0 
0 0 
.., .., 
u: (5 
:) • :) 
u- 50 •• u- 50 • • 0 0 • 
. - • • 
•• ••• • 
.t . • • • 
• • ••••• • 
i •• 
0 0 
Nonunion Union Nonunion Union 
Figure 4.1: The numbers of CFU-F (A) and CFU-O (8) colonies in nonunion 
and union groups 
The increase in CFU-F count in nonunion was not reflected on the CFU-O / 
osteoprogenitor numbers. Horizontal bars represent median values. 
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4.1.3 Differences in CFU-F colon~ sizes between nonunion and 
union groups 
A B 
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p=O.7964 p=O.4468 
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Figure 4.2: Measurement of the s izes of CFU-F colonies in nonunion and 
union groups 
A: 10mm x 10mm group. B: 7.5mm x 7.5mm group. C: 5mm x 5mm group. 0: 
2.5mm x 2.5mm group. A Significant increase of the 5mm x 5mm colonies was 
noted in the nonunion group. Colonies were stained on day 14 and scored using 
the grid as described in section 3.13. 
There were more of the larger-sized CFU-F colonies (10mm x 10mm and 
7.5mm x 7.5mm) in the union group when compared to the nonunion group (not 
Significant, p=O.7964 and p=0.4468, respectively). On the other hand, small 
sized colonies (5mm x 5mm and 2.5mm x 2.5mm) were increased in the 
nonunion group as compared to union patients. The difference in colony 
nUmber between the two groups was of statistical significance in the 5mm x 
5mm group (p=O.0277). So, it appeared that CFU-F colonies in the union group 
were more proliferative, hence the larger size of individual colonies. 
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Concurrently, the predominance of smaller sized colonies in the nonunion group 
suggested decreased MSC proliferation or early senescence. Photographs of 
representative culture dishes are shown on Figure 4.3. It shows the higher 
number and more frequent small sized colonies in the nonunion group. Fewer 
colony numbers and a predominance of large sized colonies can be noted in the 
union group. 
A B 
!! 
Figure 4.3: Scanned dishes showing numbers and sizes of colonies in 
representative nonunion and union patients 
A. Nonunion. B. Union. Note the more numerous small sized colonies in the 
nonunion patient's sample and the larger, less numerous ones in the union 
patient's sample. 
The proportions of small colonies as a percentage of total colonies in both 
patient groups were calculated Figure 4.4. It was found that in the nonunion 
group, the small sized CFU-F colonies (5mm x 5mm and 2.5mm x 2.5mm) 
represented an average 83% (67%+18%, respectively) of the total colonies 
compared to 17% large colonies (10mm x 10mm and 7.5mm x 7.5mm, 
5%+12%, respectively) . In contrast, in the union group, the small sized colonies 
represented an average 62% of total colonies (47%+15%) compared to 38% 
large colonies (4%+34%). These data confirmed that colony sizes in nonunion 
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patient samples were skewed towards smaller colonies. Altogether, these data 
showed an increased number of smaller sized CFU-F colonies in the nonunion 
group. Based on these findings it was speculated that this may represent a 
hasty attempt by the body to heal itself by producing more mesenchymal 
progenitors in order to improve its healing power. This could happen however at 
the expense of producing fully formed colonies that are capable of normal 
proliferative capacity. 
Nonunion Union 
• % of 10 mm colonies 
• % of 7.5 mm colonies 
• % of 5 mm colonies 
• % of 2.5 mm colonies 
Figure 4.4: Pie charts showing distributions of CFU-F colonies according 
to size in nonunion and union groups 
Total colonies were considered as 100% and different size colonies are shown 
as a percentage of total. 
4.1.4 Evaluation of the number of cells per colony in nonunion and 
union groups 
Colony size represents an indirect measure of progenitor cell proliferation and is 
determined not only by the number of cells forming each colony, but also by 
sizes of cells in the colonies and relative distances between the cells . The 
number of cells in 22 CFU-F colonies representing both patient groups was 
therefore enumerated and the results are shown in Table 4.2 and Table 4.3. 
Assuming each CFU-F colony originated from one MSC, population doublings 
(PDs) were worked out using the formula described in section 3.14. 
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Table 4.2: Enumeration of number of cells per colony in the nonunion 
group of patients 
10mm C1I 7.Smm C1I Smm C1I 2.Smm C1I C1I Q. Cl Cl Cl Cl 
x E x E x III X E E ... C1I C1I C1I ~ ns 9 > 7.Smm* > 5mm* > 2.5mm* C/) 10mm* « « « « f-. 
TR014 0 0 0 0 0 0 250 150 200 100 100 100 
TR016 0 0 0 550 650 600 350 400 375 150 50 100 
t-
TR019 800 700 750 500 550 525 150 300 225 100 50 75 
t-
TR021 0 0 0 0 0 0 200 250 225 150 100 125 
TR024 0 0 0 650 650 650 200 250 225 150 50 100 
TR027 800 - 800 450 550 500 200 300 250 150 50 100 
TR031 800 700 750 550 350 450 200 150 175 0 0 
t-
TR032 0 0 0 450 600 
t-
525 250 350 300 50 50 50 
TR038 0 0 0 600 550 
f-
575 400 300 350 100 50 75 
TR039 
f-. 
0 0 0 550 - 550 150 150 150 100 - 100 
TR053 
i--
0 0 0 0 0 0 200 250 225 50 50 50 
Average Cells I 
COlony 
t-
766.67 546.88 245.45 87.5 
Po 9.6 9.1 7.9 6.5 
'--
*two representative colonies are shown 
Table 4.3: Enumeration of number of cells per colony in union group of 
patients 
r--
.!l! 10mm C1I 7.5mm C1I 5mm C1I 2.5mm C1I 
a. Cl Cl Cl Cl 
E x E x III X E x E ... 
~ 9 C1I C1I C1I C1I 10mm* > 7.5mm* > 5mm* > 2.5mm* > 
~ « « « « 
TR018 0 0 0 600 650 625 350 250 300 50 100 75 
'-:=-
TR022 0 0 0 600 650 625 350 250 300 150 150 150 ~ TR023 0 0 0 350 350 200 300 250 50 100 75 
'-:=-
TR025 0 0 0 400 500 450 250 200 225 50 100 75 
-=-TR033 0 0 0 0 0 0 0 0 0 50 50 50 ~ TR035 800 850 825 500 600 550 150 100 125 50 50 ~ TR042 0 0 0 0 0 0 300 250 275 50 50 50 ~ TR043 750 700 725 500 600 550 350 400 375 100 150 125 ~ TR044 800 850 825 500 450 475 350 200 275 50 50 50 ~ 0 0 0 600 600 600 350 250 300 50 50 50 
TR046 0 0 0 0 0 0 200 300 250 100 50 75 h:-:---
Average Cells I 
COlony 791 .67 528.13 267.5 75 ~ 
9.6 9 8.1 6.2 
* two representative colonies are shown 
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On analysis of the cell per colony data for the nonunion group of patients (Table 
4.2), an average 10mm x10mm colony from those patients consisted of 
approximately 767 cells, equivalent to approximately 9.6 divisions/population 
doublings (POs) of an original colony-forming cell. An average size of the 
7.Smm x 7.Smm colonies was S47 cells, the respective values for the Smm x 
Smm, 2.Smm x 2.Smm colonies were 246 cells and 88 cells, the latter 
equivalent to 6.S POs. 
Very similar findings were obtained from looking at the cell per colony data for 
the union group of patients (Table 4.3). An average 10mm x10mm colony from 
union patients consisted of approximately 792 cells, equivalent to approximately 
9.6 POs. A 7.Smm x 7.Smm, Smm x Smm and 2.Smm x 2.Smm colonies 
consisted of approximately S28, 268 and 7S cells, the latter representing 6.2 POs. 
In both nonunion and union samples, POs were proportional to the colony size 
(Table 4.2 and Table 4.3). This demonstrated that the difference in colony sizes 
between the four different colony size groups was due to the higher number of 
cells per colony and not to due to an increase in the individual cell size. This 
additionally confirmed that progenitors forming the largest colonies were indeed 
the most rapidly growing, whereas those forming smaller colonies were growing 
much slower. 
The combined PO data are shown on Figure 4.S. Altogether they show that the 
predominance of smaller colonies in the nonunion group was not because of the 
smaller size of cells forming those c,?lonies or their more compacted 
distribution. Similarly, large colonies in the union group were not because of the 
larger size of cells forming colonies or higher distances between the cells within 
the colonies. In the opposite, these data showed that the colony size 
measurement technique used in this study was adequate to evaluate 
proliferative capacities of colony-forming progenitors. From this data, it can be 
Concluded with a high degree of confidence that CFU-F progenitors in nonunion 
patients were in average less prOliferative, compared to patients with united 
fractures. 
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Figure 4.5: Evaluation of cumulative population doublings (A) and 
population doubling time (PDT) of colony forming cells in nonunion and 
union groups 
Graphs show the same doubling capacity of cells forming small and large 
colonies in both nonunion and union groups indicating that grid system for 
measuring colony size was adequate for comparing CFU-F proliferative 
capacities in these two groups of patients. 
All four colony categories from both nonunion and union groups were examined 
microscopically. There were no differences in colony morphology between 
nonunion and union in the corresponding groups. Representative 
microphotographs of colonies of nonunion and union groups are shown on 
Figure 4.6. 
Overall, CFU-F data showed that the 8M of nonunion patients was 
characterised by an increased number of less-proliferative CFU-F progenitors . 
This possibly represented a body's response to heal the fracture, but this 
response was not sufficient, since the produced CFU-F progenitors had 
proliferative capacity that was lower than normal. 
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Figure 4.6: Microphotographs of colonies from nonunion and union 
groups 
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4.1.5 Evaluation of the sizes of CFU-O colonies in nonunion and 
union patients 
Similar analysis of colony sizes was performed for CFU-O/osteoprogenitors. For 
this assay dishes were processed and colonies stained as described in section 
3.11. Colonies were stained for ALP on day 14 and the results are shown in 
Figure 4.7. 
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Figure 4.7: CFU-O colony numbers in nonunion group compared to 
unions 
A: 10mm x 10mm group. B: 7.Smm x 7.Smm group. C: Smm x Smm group. 0: 
2.Smm x 2.Smm group. 
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As mentioned previously, no statistical differences between nonunion and union 
groups were found for the total number of CFU-O (Figure 4.1 B) . Using the grid 
system, the distribution of CFU-O colonies according to size in both groups was 
analysed . None of those results reached statistical significance, but a general 
trend of increased number of "bigger" CFU-O colonies in the union group was 
noted (Figure 4.7 and Figure 4.8) . This shows that despite the increase in 
number of smaller CFU-F colonies in the nonunion group, they were not 
"osteogenic" (i.e. not CFU-Os). One can speculate that these small colonies 
have lost their osteogenic capacity or were pre-senescent. This can be the 
reason behind the nonunion happening in the first place, or it could be the result 
of the body's hasty response to nonunion. It is hard to immediately resolve 
these issues as a prospective study needs to be arranged whereby BM samples 
are collected from all fracture patients at the time of initial fixation and following 
up BM samples to be collected if they develop atrophic nonunion. 
Nonunion Union 
• % of 10 mm colonies 
• % of 7.5 mm colonies 
• % of 5 mm colonies 
• % of 2.5 mm colonies 
Figure 4.8: Pie chart showing the distribution of CFU-O colonies 
according to size in nonunion and union groups. 
Altogether, these results showed that CFU-O colonies were distributed almost 
identically in both groups. Based on the significant increase in smaller CFU-F 
nUmbers in the nonunion groups, one would have assumed that these small 
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colonies were osteogenic. However, the result showed that they were not and 
that increase in total colony number in nonunion patients was not translated into 
an increase in osteogenic function. 
4.1.6 Confirmation of the CFU-F colony data using flow cytometry 
In these experiments BM aspirates from 7 patients suffering nonunion and 10 
long bone fracture union patients (used as controls) were used. Flow cytometry 
was performed using frozen samples of MNCs according to protocol described 
in section 3.20. 
The results for MSC enumeration based on CD4S'owCD271 + cell phenotype are 
shown on Figure 4.9. The frequency of these cells in the nonunion group was 
slightly higher than the union group (median values of 0.02% and 0.01S%, 
respectively, p=0.8070). Although statistical significance was not reached using 
flow cytometry testing, these results support the CFU-F findings described 
earlier. 
The differences in frequencies of CD4S'owCD271 + cells were next tested to 
investigate if they were related to gender groupings. Therefore, the numbers of 
CD4S'owCD271 + cell in female and male patients in the union group were 
compared and no significant differences were found (p=1.0). It was therefore 
concluded that the differences between nonunion and union groups could not 
be attributed to gender composition of these two groups. 
The frequencies of CD4S'owCD271 + cells."ln BM MNC fraction could not be 
directly compared to the numbers of CFU-F/ml of aspirate, therefore the flow 
cytometry data was converted to derive the numbers of CD4S,owCD271 + cells/ml 
of marrow using the data on the numbers of MNCs obtained from 1 ml of 
aspirate for all patients studied. MNC counts were performed after samples 
Were subjected to lymphoprep and before the samples were frozen. No 
Significant differences in MNC counts and viabilities after de-frosting were 
observed between nonunion and union groups (p=1.000 and 0.1143, 
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respectively). The converted data for the numbers of CD451owCD271 + cells/ml of 
marrow are shown on Figure 4.10. 
Statistical analysis revealed that the number of CD451owCD271 + cells/ml of 
marrow in the nonunion group was higher than in the union group (median 
values 1022 cells/ml and 309 cells/ml , respectively, p=0.7577) . Although 
statistical significance was not reached , this result is consistent with CFU-F 
findings demonstrating relative increase of MSCs in nonunion patients 
compared to unions. Although flow cytometry-based enumeration of MSCs was 
broadly consistent with CFU-F data, it has lesser value since flow cytometry did 
not provide any information of the proliferative capacity of these MSCs. In 
contrast, this information is obtainable from CFU-F assays and can be 
discerned from measuring the sizes of individual colonies. 
CD271 + cells 
p=O.8070 
0.11 
~ 0 0.10 • 
II) 0.09 
a; 0.08 CJ 
+ 0.07 
"I'"' 0.06 • '" N 0.05 • C 
0 0.04 •• ~ 
0 0.03 • • 
'in 0.02 • • ~ C 0.01 • 0 ••• 0.00 
Nonunion Union 
Figure 4.9: Enumeration of CD4SlowCD271+ cells in nonunion and union 
patients represented as a percentage of CD4SIowCD271+ cells in relation to 
MNCs 
Despite higher average numbers in nonunion patients, statistical significance 
was not reached. Horizontal bars represent median . 
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Figure 4.10: Enumeration of CD4SlowCD271 + cells in nonunion and union 
patients represented as the number of CD4SlowCD271+ cells per millilitre of 
8M aspirate 
Despite higher average numbers in nonunion patients, statistical significance 
was not reached Horizontal bars represent median. 
4.1.7 Clinical correlations 
Clinical data relevant to the development of nonunion was collected for patients 
who participated in the aforementioned studies. Correlations were drawn in an 
attempt to identify an underlying "clinical" factor that could contribute to the 
development of nonunion. A summary of clinical data is presented in Table 4.4. 
In this study, union was defined by clinical union parameters; the disappearance 
of pain and movement at the fracture site whereas nonunion was diagnosed 
when those symptoms persisted for more than 9 months post fracture fixation , 
together with radiographs showing lack of bridging callus in at least 3 cortices. 
Time to union was defined as the time between the definitive fracture fixation to 
the time of clinical union as documented in patents' follow up clinic notes. 
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For this study, a total of 22 patients were recruited, 11 suffered aseptic atrophic 
long bone nonunion (nonunion group) and 11 with previous long bone fractures, 
that were treated operatively and have united without delay (union group). The 
nonunion group was formed of 5 females and 6 males, age range from 19 to 63 
years, mean age of 40.5 years and median age of 43 years and the union group 
was formed of 8 females and 3 males, age range from 18 to 56 years, mean 
age of 39.7 years and median age of 41 years. Eight patients from the nonunion 
group and 5 from the union group were smokers. The time to union in the union 
group ranged from 6 to 11 weeks, mean of 8.4 weeks and median 8 weeks. 
Five of the nonunion group patients failed to unite at the time of writing 
(maximum follow up was 7 months). For the remaining nonunion group patients, 
time to union ranged from 60 to 264 weeks, mean of 144 weeks and median 
136 weeks. Injuries in the nonunion group were caused by road traffic accidents 
(RT A) in 5 patients, sports injuries in 2 patients, pedestrian accident in 2 
patients, motorbike accidents in 1 patient and fall in 1 patient. Injuries in the 
union group were due to RTA in 3 patients, sports injuries in 1 patient, 
pedestrian accident in 2 patients, work related injury in 1 patient and fall in 3 
patients. None of those patients were on corticosteroid or NSAID treatment; all 
but three were non alcohol drinkers. 
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Table 4.4: Clinical demographics of patients participating in the nonunion 
vs union study. 
Sample Gender Age Study Smoking Time to Causative (Type )& Bone 
10 group union Injury fractured 
(weeks) 
TR014 male 31 Nonunion Yes 264 RTA (Closed) Femur 
TR016 male 19 Nonunion Yes 60 RTA (Closed) Femur 
TR019 female 50 Nonunion Yes 168 pedestrian (open Gilla) Tibia 
-TR021 male 22 Nonunion Yes N/A RTA (open Gil) Femur 
TR024 female 43 Nonunion Yes 116 Sports (open GI) Tibia 
i--
TR027 male 33 Nonunion No 100 pedestrian (Closed) Femur 
TR031 male 62 Nonunion Yes 156 Fall (Closed) Femur 
TR032 male 63 Nonunion Yes N/A RTA (Closed) Tibia 
i--
TR038 female 58 Nonunion 
r-
Yes N/A RTA (Closed) Tibia 
TR039 female 44 Nonunion No N/A motorbike (open Gil) Tibia 
I--
TR053 female 21 Nonunion 
r-
No N/A Sports (Closed) Femur 
TR018 female 44 Union Yes 7 RTA (Closed) Tibia 
t--
TR022 female 46 Union No 8 - Fall (Closed) Tibia 
-TR023 female 41 Union No 10 RTA (Closed) Femur 
-TR025 male 33 Union Yes 7 RTA (Closed) Femur 
t--
TR033 female 39 Union No 8 pedestrian (open Gil) Tibia 
-TR035 female 42 Union Yes 9 motorbike (open Gllla) Tibia 
-TR042 female 46 Union No 8 Fall (Closed) Femur 
-TR043 male 18 Union Yes 6 Work (Closed) Tibia 
--TR044 female 56 Union No 8 Sports (Closed) Tibia 
--TR045 male 41 Union Yes 10 Fall (Closed) Femur 
-=--TR046 female 31 Union No 11 Pedestrian (Closed) Femur 
N/A - data not available as fracture was not united at the time of writing 
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The effect of cigarette smoking on the total number and sizes of CFU-F colonies 
in both nonunion and union groups was studied (Figure 4.11). There was a 
trend for an increase in the CFU-F numbers in the smokers when compared to 
the non-smokers in both nonunion and union groups. There was a statistically 
significant increase in number of the smallest (2.5mm x 2.5mm) colonies in the 
union group amongst the smokers (p=O.0219) and a similar trend was noted in 
the nonunion group. Due to the small sample size, the remaining results failed 
to reach statistical significance. 
Furthermore, correlations were drawn between the time to union, total CFU-F 
colonies and colony sizes in the union group. The total CFU-F count and the 
number of 10mm x 10mm colonies seemed to be inversely proportional to the 
duration of fracture healing. In other words, the more CFU-F colonies (in 
particular the large sized 10mm x 10mm ones), the more likely it was for the 
fracture to heal in a shorter period of time. The opposite was noticed with the 
5mm x 5mm colonies. The more of those colonies present, the longer it took for 
the fractures to heal. Due to the small sample size, no statistical significance 
was reached, and because this work has not been reported before in the 
literature, a power calculation was not possible prior commencing this study. 
Upon looking back on all the results presented so far in this study, one can 
notice certain trends and observations. In general, nonunion patients have more 
of the small sized CFU-F colonies, which may be less proliferative and 
osteogenic, whereas the union patients have fewer total CFU-F numbers, but 
more of the larger, more proliferative ones. Similar findings were noticed in 
patients who smoked. They had more total, colonies and a significant increase 
of the small, 2.5mm x 2.5mm colonies in the union group. When the observation 
that the time to union was found to be longer with patients who had more of the 
small sized colonies and was found shortened with those who had more of the 
large sized ones, more questions maybe asked. How effective are the small 
sized colonies and how much do they contribute to the fracture healing 
process? One may even argue that the presence of the small sized colonies 
pose a threat to union. May these observations be used as a predictor for 
nonunion in the future to identify the fracture at highest risk for developing 
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nonunion and hence justify close patient follow up and monitoring and perhaps 
early surgical intervention if complications were to develop? These questions 
will be addressed in future studies. 
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Figure 4.11: BoxpJots showing the effect of smoking on CFU-Fs in 
nonunion and union groups 
Graphs on the left are representative of the nonunion group whereas those on the 
right represent union group. A, B: total CFU-F counts, C, 0: 10mm x 10mm group, 
E, F: 7.5mm x 7.5mm group, G, H: 5mm x 5mm group, I,J : 2.5mm x 2.5mm group. 
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Figure 4.12: Graphs showing the effect of the CFU-F numbers and sizes 
on the t ime to union in the union group 
A: Total CFU-F count, B: 10mm x 10mm group, C: 7.Smm x 7.Smm group, D: 
Smm x Smm group and E: 2.Smm x 2.Smm group. 
86 
CHAPTER 5 
RESULTS OF BMP-7 STUDY 
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5.1 EFFECT OF BMP-7 ON BM MSCS 
5.1.1 Validation of osteogenesis assays 
Osteogenesis assay was performed in duplicate (duplicate dishes) and calcium 
assay was performed in triplicate (triplicate wells). Variability between replicates 
was first assessed to investigate the accuracy of these assays to measure the 
expected effects. 
5.1.2 Calcium assay performance 
A standard curve built using Ca++ standards from Sigma showed good linearity 
and consistency between . the different experiments. An example of 6 
experiments (3 from the nonunion group and 3 from the union group) is shown 
in Table 5.1. 
Table 5.1: Variability between Ca++ assay triplicates 
Optical density (OO) readings for a random group of experiments, standard 
deviation (SO) and coefficients of variation (CV) for triplicate wells. 
001 002 003 Mean 00 (SO) (CV) 
0.235 0.244 0.24 0.24 0.0045 1.88 
0.229 0.228 0.229 0.23 0.0006 0.25 
0.258 0.266 0.261 0.26 0.0040 1.55 
0.246 0.239 0.247 0.24 0.0044 1.79 
0.238 0.24 0.24 0:24 0.0012 0.48 
0.24 0.25 0.24 0.24 0.0046 1.90 
The results show a very good statistical intra-assay performance which reflects 
the high degree of pipetting accuracy achieved between Ca++ assay triplicates. 
The CV value ranged from 0.3% to 1.9% with an average of 1.3%, which was 
significantly below the accepted level of 5%. 
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5.1.3 Osteogenic assay performance 
Osteogenic assay is a 14-day in vitro functional assay used as a measure of 
osteogenesis. The precision of the results depends on the number of replicates 
set-up for each dose of BMP-7 treatment (duplicate dishes were used). 
Performing the assay in duplicate dishes produced variable CVs ranging 
between 1 % to 37% and an average CV of 9% (Table 5.2). 
Table 5.2: Intra-donor variability between duplicate osteogenic assay 
dishes for a random group of experiments 
Calcium production in duplicate dishes (J.Jg/ml), SO and CV between duplicate 
dishes. 
Calcium (J.Jg/ml ) Calcium (J.Jg/ml) Mean SO CV 
Dish 1 Dish 2 
8.22 7.98 8.10 0.17 2.10 
8.46 8.34 8.40 0.08 1.01 
11.74 13.44 12.59 1.20 9.55 
26.01 24.28 25.15 1.22 4.86 
12.07 20.52 16.30 5.98 36.67 
9.39 9.13 9.26 0.18 1.99 
~ 
The average CV remained below the acceptable level of variability for this 
assay (10%, based on previous experience from the laboratory were this work 
Was carried out). Variability could have been further reduced by performing 
osteogenic assay in triplicates; however this would have required higher 
volumes of samples and higher cost of osteogenic medium I BMP-7. 
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5.1.4 Effect of BMP-7 on calcium production by expanded 8M MSCs 
from union patients 
Previously-published studies investigated the effect of BMP-7 on culture-
expanded BM MSCs and observed enhanced osteogenesis following the 
addition of BMP-7 [107]. To validate these findings in this experimental system, 
pO culture-expanded MSCs from union patients were first treated with 100ng/ml 
BMP-7 or 300ng/ml BMP-7 and colorimetric calcium assays were used as a 
measure of osteogenic differentiation. Since it was not possible to use healthy 
patients as controls in this study, patients previously suffering long bone 
fractures that have united without healing complications and were re-operated 
for hardware removal were recruited as controls. During their surgeries, 
posterior iliac crest BM was aspirated as mentioned earlier. Cells from 4 donors 
were grown in NH media until confluent (pO), and the resulting expanded MSCs 
were then placed in osteogenic media where they were treated with no BMP-7, 
100ng/ml BMP-7 or 300ng/ml BMP-7. Results for individual donors are shown in 
Figure 5.1 and for all 4 donors combined on Figure 5.2. 
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Figure 5.1: The effect of BMP-7 on calcium production by expanded MSCs 
in the union group (4 donors shown separately) . 
Error bars represent osteogenic assay duplicates. *Ex - experiments performed 
with expanded MSCs. 
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The result showed that BMP-7 had no effect on culture expanded MSCs from 
union patients with the addition of either 100ng/ml or 300ng/ml (Figure 5.1). 
Average results for all the 4 donors, depicted on Figure 5.2 highlight high donor-
to-donor variability in calcium production by expanded MSCs at baseline and 
with the addition of BMP-7. 
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Figure 5.2: The effect of BMP-7 on calcium production from culture-
expanded BM MSCs from all four patients in the union group 
There was a trend showing increased calcium production by MSCs in a dose 
dependant manner. Results tested using Wilcoxon ranked non-parametric test 
showed no statistical significance. Error bars represent variation between 
donors (SO). 
5.1.5 Effect of BMP-7 on proliferation and colony formation by 
expanded BM MSCs from union patients 
These experiments were set-up as described in section 3.12 and total colony 
numbers and sizes were evaluated (Figure 5.3 and Figure 5.4). Similar to 
calcium assay results, CFU-F results showed no effect with the addition of 
either 1 OOng/ml or 300ng/ml. 
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Figure 5.3: The effect of BMP-7 on colony formation by expanded MSCs in 
the union group (3 donors shown separately) 
Error bars represent CFU-F assay duplicates. 
The effects of BMP-7 on CFU-F colony sizes were also evaluated and results 
are presented in Figure 5.4. As mentioned previously, the sizes of colonies 
reflect the proliferative capacity of colony-forming MSCs. 
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Figure 5.4: Pie chart showing the effect of BMP-7 on colony sizes by 
culture-expanded MSCs from union patients 
Overall, these data showed no effect of addition of either 100ng/ml or 300ng/ml 
BMP-7 on the proliferation and colony formation by expanded MSCs from union 
patients. 
5.1.6 Effect of BMP-7 on calcium production by expanded BM MSCs 
from nonunion patients 
Similar to union patients, culture-expanded MSCs from nonunion patients were 
used to assess the effects of BMP-7 on calcium production. Calcium production 
by MSCs from 3 different donors is shown on Figure 5.5 and for all 3 donors 
combined is shown on Figure 5.6. 
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Figure 5.5: The effect of BMP·7 on calcium production by expanded MSCs 
in the nonunion group (3 donors shown separately) 
Error bars represent osteogenic assay duplicates. 
The results show that expanded MSCs from nonunion patients failed to respond 
to BMP-7 at all. 
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Figure 5.S: The effect of BMP-7 on calcium production from culture-
expanded BM MSCs from nonunion patients 
No effects were observed with the addition of BMP-7. Error bars represent 
variation between donors (SD). 
5.1.7 Effect of BMP-7 on the proliferation and colony formation by 
expanded BM MSCs from nonunion patients 
As for all similar experiments described in this section, colony formation was 
assessed in several duplicate dishes and colony sizes were evaluated using 
scoring grids. Colony number and sizes are presented in Figure 5.7. 
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Figure 5.7: The effect of BMP-7 on colony formation by expanded MSCs in 
the nonunion group (3 donors shown separately) 
Error bars represent CFU-F assay duplicates. 
The results show that expanded MSCs from nonunion donors failed to respond 
to BMP-7. This was consistent with calcium data showing that MSCs cultured 
from BM of nonunion patients were unresponsive to BMP-7. 
5.1.8 Effect of BMP-7 on calcium production from fresh uncultured 
BM MSCs from nonunion patients 
Although most investigations are still performed using MSCs expanded in 
culture [107], it is well-known that culture-adaptation affects MSC characteristics 
and leads to gradual senescence [164]. Additionally, BMP-7 is acting on native 
MSCs when used clinically during surgery [152-154] . Based on these 
considerations and to reflect clinical situations more closely, next set of 
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experiments was designed to explore the effect of BMP-7 on fresh, uncultured 
MSCs from nonunion patients. In these experiments, 3001-11 of fresh 8M from 
long bone fracture nonunion patients (N=6) were seeded in 10ml of DMEM/2% 
FCS media and then transferred to osteogenic media containing, no BMP-7, 
100ng/ml BMP-7 or 300ng/ml BMP-7. End-point assays (calcium assay and 
CFU-F assay) were performed as described above. Calcium production by 
MSCs from 6 different nonunion patients is shown on Figure 5.8 and for all 6 
donors combined in shown on Figure 5.9. 
The results showed no trends for an increased calcium production by fresh 
MSCs from nonunion patients with the addition of BMP-7 (Figure 5.8). 
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Figure 5.8: The effect of BMP-7 on calcium production by fresh MSCs from 
6 nonunion patients 
Error bars represent osteogenic assay duplicates. 
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Figure 5.9: The effect of BMP-7 on calcium production from fresh BM 
MSCs from nonunion patients 
No effects were observed with the addition of BMP-7. Error bars represent 
variation between donors (SD, n=6). 
The mean calcium production for all 6 donors depicted on Figure 5.9 show no 
up-regulation in calcium production by fresh MSCs from nonunion patients with 
the addition of BMP-7. This is consistent with results obtained from expanded 
MSCs from nonunion patients and with MSCs from the union group. Overall, 
these data indicated that MSCs from nonunion patients were unable to produce 
calcium in response to BMP-7. 
5.1.9 Effect of 8MP-7 on the proliferation and colony formation by 
fresh non expanded 8M MSCs from nonunion patients 
In these experiments, 300\-11 of fresh BM from long bone fracture nonunion 
patients were seeded in NH media containing BMP-7. On day 14, colonies were 
counted and their sizes measured as described earlier. The results for individual 
donors are shown Figure 5.10. 
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Figure 5.10:The effect of BMP-7 on colony formation by fresh, non-
expanded MSCs in the nonunion group (6 donors shown separately) 
Error bars represent CFU-F assay duplicates. 
The results show that the addition of BMP-7 has not affected colony formation 
in all donors. 
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Figure 5.11: The effect of BMP-7 on colony formation from fresh BM MSCs 
of nonunion patients 
No effects were observed with the addition of BMP-7. Error bars represent 
variation between donors (SD, n=6). 
Overall, these results showed, that similar to calcium production data, MSCs 
from nonunion patients have failed to respond to BMP-7. 
Finally, the effect of BMP-7 on the sizes of CFU-F colonies, reflecting their 
proliferative rate, was investigated (Figure 5.12). There was no significant effect 
noted by the addition of BMP-7 in either 100ng/ml or 300ng/ml concentrations 
when compared to no BMP-7 controls. The colony results from a representative 
nonunion patient are shown on Figure 5.13. 
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Figure 5.12: Pie chart showing the distribution of MSC colonies according 
to size by fresh, non-expanded MSCs from nonunion patients 
Figure 5.13: Scanned dishes of CFU-F from a representative nonunion 
patient showing the effect of addition of BMP-7 
A: No 8MP-7, 8 : 100ng/ml 8MP-7, C: 300ng/ml 8MP-7. No significant change 
was noted between all three dishes illustrating that the addition of 8MP-7 does 
not affect the number of CFU-F colonies from nonunion patients. 
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CHAPTER 6 
RESULTS OF MSC 
CIRCULATION STUDY. 
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6.1 STUDIES TO EXPLORE THE CIRCULATION OF MSCS 
IN THE BLOOD IN HEALTH. ORTHOPAEDIC 
PROCEDURES AND EARLY RA 
The presence or absence of circulating MSCs in various orthopaedic conditions, 
in early rheumatoid arthritis patients not on disease modifying treatment and in 
healthy controls were studied and results are shown in this chapter. The 
orthopaedic operating theatre was a unique environment where skeletal 
manipulation took place and thus provided a ready clinical model to assess 
whether MSCs circulation may be a biophysical process. 
6.1.1 Group I 
Group I, was comprised of 12 patients suffering long bone fracture nonunion 
and undergoing reaming of the sound femur with RIA for bone graft harvesting. 
Out of the 12 patients, 8 showed evidence of circulating MSC colonies in their 
lower limb venous blood (66.67%) and in only 2 out of the 12 patients (16.67%) 
circulating MSCs were identified in their upper limb venous blood. 
In all 12 patients, a total of 216.9 x 106 MNCs, from an original 120ml of lower 
limb venous blood collected were seeded and a total of 20 MSCs were 
identified. An average of one MSC colony was present in every 10.8 x 106 
MNCs seeded. Volumetrically, total of 120ml of lower limb venous blood was 
collected from all the patients and only 20 MSC colonies were identified (one 
MSC colony per 6ml of blood). The number of MSCs found in the lower limb 
venous blood per MNC seeded for individual participating patients is shown in 
Table 6.1. 
A total of 179.7 x 106 MNCs, from an original volume of 120ml of blood, from 
the upper limb venous circulation from all patients were seeded and only 2 MSC 
colonies were identified. So, one MSC colony per 89.85 x 106 MNCs was found 
(one MSC per 60ml of blood i.e. 10 fold less than in LL). It is worth mentioning 
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that those 2 patients have shown evidence of circulating MSCs in their lower 
limb venous blood at a higher concentration than that in the upper limb venous 
blood, matched images from one patient are shown in Figure 6.1. This finding 
supports the evidence that MSCs are filtered in the lungs as they pass from the 
lower limb into the upper limb venous system. The amount of MNCs and MSCs 
in the upper limb venous circulation (identified per patient) are summarized in 
Table 6.1. 
Odds ratio statistical testing was carried out comparing the number of samples 
positive for MSCs in LL compared to UL upon "exposure" to reaming with RIA. 
Assuming sample independence Oustified by the extreme rarity of MSCs in the 
blood), odds ratio of 10 was found, with a 95% confidence interval and a p value 
of 0.036. One can conclude that there is an increased chance of finding MSCs 
in the lower limb venous blood when compared to the upper limb venous blood 
following reaming with RIA. 
It can be deduced that MSCs do circulate in both lower limb and upper limb 
venous systems of nonunion patients at very low concentration after reaming 
with RIA. They are present at an even lower concentration in the upper limb 
venous system as they are possibly filtered in the lung and subsequently filtered 
in the tissue capillary beds. This can raise the question of how feasible would it 
be to introduce MSC cellular therapy for intravenous injection. The total number 
of MSCs in the upper limb venous blood as compared to the lower limb venous 
blood in each of the 12 patients of this study is shown in Figure 6.2. 
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Table 6.1: Total number of MNCs seeded and MSC colonies observed in 
LL and PB of group I patients. -
Total MNCs Total 
MNCs Frequency Frequency 
MSC seeded MSC 
seeded in LL, 1 in UL, 1 
Sample Colony from Colony 
from LL cell per cell per 
10 Numbers UL Numbers 
blood, 
observed 
MNC, in 
blood, observed 
MNC, in 
in 106 106 106 
in LL in 106 in UL 
TR016 12.4 3 4.1 12.1 1 12.1 
TR019 16.0 3 5.3 17 1 17.0 
TR021 4.7 0 0 5.5 0 0 
TR024 10.4 1 10.4 9.1 0 0 
TR027 11.3 0 0 7.1 0 0 
TR028 13.7 1 13.7 4.4 0 0 
TR031 10.1 1 10.1 16.6 0 0 
TR032 8.5 4 2.1 8.5 0 0 
TR038 4.1 0 0 4.5 .. 0 0 
TR039 37.3 4 9.3 47.6 0 0 
TR040 53.9 0 0 27.3 0 0 
TR053 34.3 3 11.4 20.5 0 0 
106 
Upper limb Lower limb 
Figure 6.1: Scanned Crystal violet stained CFU-F colonies (A and B) and 
microscopic images of same colonies (C and D) from the same patient 
Arrows pointing at CFU-F colonies. Note 3 CFU-F colonies in the femoral 
venous blood sample compared to 1 in the peripheral venous blood suggesting 
possible filtration of MSC colonies in the lung. 
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Figure 6.2: Number of MSC colonies in 10ml of lower limb compared to 
10ml of upper limb venous blood in all 12 nonunion patients after reaming 
with RIA for bone graft harvesting (Group I) 
More MSC colonies were found in the LL as compared to the same volume of 
UL. When colonies were evident in the peripheral blood, this was only in the 
context of being also present, at a higher level in the femoral vein . This likely 
represents filtration in the lungs and peripheral tissue capillary beds. 
6.1.2 Group II 
This group was formed of 12 patients where recent or intra-operative skeletal 
trauma including reaming did not take place and samples were collected before 
commencement of surgery. A total of 24 samples from 12 patients were 
collected. Out of the 12 LL samples, 5 patients showed evidence of ci rculating 
MSCs (41.67%) and only 1 out of the 12 UL samples showed evidence of 
circulating MSCs (8 .33%). The latter case with UL MSCs also had MSCs 
evident in the LL femoral vein circulation . 
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An average of 1 MSC colony was present in every 58.4 x 106 MNCs seeded 
from the femoral venous blood compared to an average of 1 MSC colony per 
718 x 106 MNCs in peripheral blood. In the 120ml of femoral venous blood 
collected from all patients, 10 MSC colonies were present, that is an average of 
1 MSC colony per 12ml of blood, whereas only 1 MSC colony was identified in 
the 120ml of PB from the same patients (10 fold less). The total number of 
MNCs seeded and MSCs identified in both the LL and PB samples for this 
group of patients is shown in Table 6.2. 
Odds ratio statistical analysis of these results was done assuming 
independence of the samples, which again, was justified by the extreme rarity of 
MSCs in the blood. An odds ratio of 2.5 was found with a 95% confidence 
interval, p=0.32. Unlike the results from Group I, these findings have failed to 
reach statistical significance. Further odds ratio testing was carried out 
between the LL sample results from both Group I and II; an odds ratio of 4, with 
a 95% confidence interval and p=0.11. 
These findings prove even more that MSC circulation is an extremely rare entity 
in the orthopaedic setting. The lower limb venous circulation adjacent to lower 
limb skeletal pathology may contain more MSCs when compared to the upper 
limb venous system. 
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Table 6.2: Total number of MNCs and MSC colonies identified in LL and 
PB in patients undergoing various orthopaedic procedures not involving 
reaming 
Total MNCs Total 
MNCs Frequency Frequency 
MSC seeded MSC 
seeded in LL, 1 in PB, 1 
Sample Colony from Colony 
from LL cell per cell per 
10 Numbers PB Numbers 
blood, 
observed 
MNC, in MNC, in 
in 106 106 
blood, observed 
106 
in LL in 106 in PB 
TR029 20.2 4 5.1 9.4 0 0.0 
TR030 16.0 0 0 16.0 0 0.0 
TR034 158.1 0 0 114.4 0 0.0 
TR036 34.4 0 0 179.2 0 0.0 
TR037 7.9 0 0 16.9 1 16.9 
TR041 45.3 2 22.7 46.6 0 0.0 
TR047 31.5 . 1 31.5 33.4 0 0.0 
TR054 70.2 0 0 70.0 0 0.0 
TR065 117.0 1 117.0 128.0 0 0.0 
TR077 15.1 0 0 16.5 0 0.0 
TR078 15.3 0 0 10.6 0 0.0 
TR080 52.5 2 26.3 77.0 0 0.0 
When one compares the results from this group to those of Group I, it is 
noticeable that the volumetric frequency of MSCs in the femoral venous blood 
has halved (1 MSC colony per 6ml of femoral venous blood versus 1 colony per 
12ml of femoral venous blood in Group II). The increase in MSC frequency in 
Group I is more likely to be the consequence of the mechanical translocation of 
the MSCs into the deep venous system as sample collection was immediately 
procured following reaming. 
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6.1.3 Group III 
None of the 11 patients suffering from early RA showed evidence of circulating 
MSC colonies in their UL venous blood samples. The total number of MNCs 
seeded in each patient is shown in Table 6.3. 
Table 6.3: Number of mononuclear cell seeded compared to the MSC 
colonies in early RA patients. 
Sample 10 Cells seeded (x 106) MSC Colony Number 
TR066 14.2 0 
TR067 26.6 0 
TR068 8.6 0 
TR069 8.7 0 
TR070 8.6 0 
TR071 7.3 0 
TR072 22.1 0 
TR073 27.6 0 
TR074 34.1 0 
TR075 25.1 0 
TR076 9.4 0 
TR066 14.2 0 
The failure to identify MSCs in peripheral venous blood of early RA patients 
argues against the findings of some authors who attributed the spread of RA to 
circulating synovial fibroblasts [129, 130]. 
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6.1.4 Group IV 
This was the healthy control group of volunteers. Upon CFU-F staining of the 
samples, there was no evidence of MSCs in their UL venous blood. Results can 
be summarized in Table 6.4. One can argue against the circulation of MSCs in 
healthy individuals. 
Table 6.4: Number of MNC seeded compared to MSC colonies in healthy 
controls 
Sample 10 Cells seeded (x 106) MSC Colony Number 
TR048 31.9 0 
TR049 44.7 0 
TR050 24.1 0 
TR055 18.3 0 
TR056 35.3 0 
TR057 23.0 0 
TR059 10.7 0 
TR060 19.8 0 
TR061 22.9 0 
TR062 7.4 0 
TR063 27.9 0 
TR064 23.3 0 
6.1.5 Macrophage like colonies 
Numerous studies have argued for the presence of MSCs in the circulation and 
it is possible that some other cell type may have been erroneously scored as 
MSC colonies. It was noted that in most of the CFU-F dishes, two distinct 
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types of colonies were identified. These colonies either had a fibroblast like or 
macrophage like morphology. Both these colony populations have plastic 
adherent properties. Fibroblast-like colonies were scored as CFU-Fs/MSCs. 
Macrophage-like colonies are shown on Figure 6.3 and were not scored due to 
their clearly distinct differences from the CFU-Fs. 
Figure 6.3: Gross and microscopic images of macrophage like colonies 
A: scanned dish showing multiple macrophage like colonies (arrows). 
B: microscopic image of the same colonies (x100 magnification). 
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CHAPTER 7 
DISCUSSION 
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7.1 DISCUSSION RELATED TO THE NUMBERS OF MSCS 
AND OSTEOPROGENITORS IN BM ASPIRATES IN 
NONUNION AND UNION PATIENTS 
The role of MSCs in the aetiology of nonunions is poorly understood. The 
questions that maybe asked by treating physicians are: do local MSCs in 
atrophic ~onunions have diminished proliferative and osteogenic capacities, 
explaining why fractures do not unite? Following from this, is this deterioration a 
systemic phenomenon affecting MSCs not only at the fracture site but also in 
the 8M? This hypothesis is plausible taking into consideration the prevailing 
views pertaining to the circulation of 8M MSCs to the sites of injury as a 
potential mechanism of repairing fractures. 
To address these questions, the first part of this study investigated the number 
and proliferative capacity of MSCs in patients suffering nonunions in 
comparison to the union group which was age and gender matched. The union 
group comprised patients who had previous long bone fractures which 
subsequently healed uneventfully. The ideal methodology to test this hypothesis 
would be to prospectively recruit long bone fracture patients and obtain 8M 
aspirates for CFU-F assays from them during their fracture fixation surgery. 
Thereafter, follow them at regular intervals until either union or nonunion is 
established (based on FDA criteria for union). This would allow a more robust 
prospective comparative analysis. 
Contrary to the original hypothesis, the studies described herein showed that 
the reservoir of 8M CFU-Fs in patients: with atrophiC nonunions was not 
numerically diminished; in fact their number was increased. Their proliferative 
capacity was however low which may explain poor healing response in vivo. 
Only one previously published study has tested a similar hypothesis and the 
results were somewhat different. In Seebach et al study [122], the number of 
CFU-Fs in the 8M of nonunion patients was found to be significantly below 
normal controls (healthy volunteers). In concordance with the current study, 
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they found lower proliferative capacity of MSCs from nonunion patients. The 
discrepancy between Seebach and the present work in respect to CFU-F 
numbers can be explained by several factors. Firstly, the group of normal 
volunteers in their study was not perfectly age-matched (mean age range for 
volunteers 32 and 33 years old for males and females and mean age range for 
nonunion patients 41 and 42 years, respectively). It is well known that the 8M 
CFU-F capacity declines with age [39], and it is possible that the observed 
lower CFU-F numbers in nonunion group of patients actually reflected age 
differences rather than nonunion-related differences. 
Secondly, the type of CFU-F assay was also different in Seebach et al study 
[122]. The authors fractionated 8M aspirates first, to obtain MNC fractions, and 
then plated the cells by cell density. In this study. direct 8M plating technique 
was used; it has an advantage over MNC plating in that minimal manipulations 
of aspirated marrow are performed, thus minimizing the loss of cells through 
centrifugation and washing steps. Of note, MNCs from nonunion patients were 
used for the flow cytometry study in this work and the trends were similar to 
CFU-F direct plating technique. So on comparison, the discrepancy in the 
results lies rather in the differences in control groups selected rather than the 
techniques used. 
It is also well-known that the CFU-F content of 8M aspirates depends critically 
on the surgical technique of actual marrow aspiration [165]. In this study the 
aspiration site was altered every 4ml, hence insuring minimal dilution with blood 
and the consistence in sample collection for all the patients and groups. No 
detail is given in Seebach study [1221 as ~o their sample collection protocol and 
if samples for volunteers and nonunion patients were collected by different 
surgeons and using different techniques; this could have also affected the 
results. Intriguingly, these authors have found massive differences in CFU-F 
numbers between normal males and females - a controversial finding, never 
documented before, despite numerous published studies on this subject [39, 
166] and certainly not observed in this study_ 
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Furthermore, the number of CFU-Fs can be dependent on the media used and 
serum in particular, which critically influences the cell attachment. Whilst 
attached though, MSCs begin to proliferate and form colonies. In this respect, 
findings in this work and Seebach et al [122] findings are very similar. Indeed, 
the proliferative capacity of MSCs in nonunion patients was found to be inferior 
to control in both studies. Remarkably, this coherence was found irrespective of 
the methods used to assess proliferation. Seebach et al [122] measured the 
sizes of colonies using digitized images and a specialised image software. In 
this study manual grading of colonies was used, from big 10mmX10mm to small 
2.Smmx2.Smm). The average numbers of cell per colony of each size was 
scored and it was proved that colony sizes were indeed reflective of the number 
of cell per colony (Le. the degree of proliferation of colony-forming cells) and not 
of cell spreading and motility leading to a bigger but less dense colonies. So, it 
can be said with a strong degree of confidence that MSCs from nonunion 
patients are indeed less proliferative. Indeed, this lack of proliferative potential 
raises the question that these cells are no longer true MSCs in that they have 
lost an intrinsic feature of stem cells, i.e. high proliferative capacity. 
The novelty of this study over Seebach et al [122] study also lies in the use of 
flow cytometry as an independent adjunct method of MSC enumeration and 
also in the assessment of the PO rate of union and nonunion CFU-Fs in culture. 
In the present work, it was shown that MSCs forming large colonies have 
undergone nearly 10 divisions during the 14-day culture period whereas MSCs 
forming small colonies have divided only 6 times. This emphasizes the 
immense heterogeneity of MSCs documented in other similar studies [167, 168] 
and shows that further work is needed to dissect the relationship between the 
proliferation potential of individual MSCs and their osteogenic properties. 
The mechanism underlying poor proliferation of BM MSCs in nonunion patients 
remains unclear. Given that MSCs were obtained from the iliac crest and not 
the fracture site then this appears to be, at least in part, a systemic problem. 
Kwong et al [169], have proposed an imbalance in the production of BMPs and 
their antagonists, but they have investigated and confirmed the validity of this 
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hypothesis at the local level, within the cartilaginous intermediate of non healing 
fractures. Hoffman et al [170] have investigated the viability, differentiation and 
gene expression profiles of osteoblasts at sites proximal to hypertrophic 
nonunions and found these to be significantly altered, with a notable down-
regulation of molecules involved in bone-related signalling pathways. The effect 
on MSCs in the BM however,' which is a distant site to the nonunion, is likely to 
be mediated via factors acting systemically via circulation. Seebach et al [122], 
have come to the same conclusion saying that "yet unidentified serum factors", 
which may affect the number of MSCs in fracture patients, including BM. The 
levels of IL-6 which are shown to correlate with trauma severity, may be one 
such factor [122], given the known inhibitory role of pro-inflammatory cytokines 
on osteogenesis [171]. It is possible that circulating levels of osteogenesis-
related growth factors like TGF-~, IGF and PDGF [170] are also involved, as 
well as inhibitory molecules, this certainly merits further investigation. 
Overall, the results of this study support the rationale for using autologous BM 
MSC injections to augment bone healing in atrophic non unions [87, 116]. 
However they advocate caution, showing that local application of autologous 
poorly-proliferative MSCs may not be the optimal _solution. Stimulation of 
patient's BM MSCs activity prior to harvesting marrow may be a better option. In 
this respect, the discovery of the serum factors responsible for systemic 
activation of MSCs is the best way forward. It also suggests that healthy 
allogenic MSCs might represent an alternative therapy source in this clinical 
setting. 
.. 
7.2 DISCUSSION RELATING TO BMP·7 
Several clinical studies have demonstrated a beneficial effect of BMP-7 on the 
healing of non unions [83, 152, 154, 172, 173] .The mechanism behind the 
action of BMP-7 in these clinical trials however, remains poorly understood. The 
second part of this study therefore addressed an issue of responsiveness of 
MSCs derived from the BM of nonunion patients to BMP-7 in comparison to 
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united fracture patients. The range of chosen concentrations of BMP-7 tested 
was within the reported in previously-published literature [107,123,174]. 
Contradictory to the findings of Zhi et al and Shen et al studies [123, 174}, no 
increase in calcium release by union MSCs with the addition of BMP-7 was 
observed. It should be noted however that to achieve statistical significance in 
calcium production up-regulation, Zhi et al had to increase the assay duration to 
35 days, above the normal assay length, whereas their day-17 results were very 
similar to the results presented here. Shen et al did not evaluate calcium 
production quantitatively; only microphotographs of cultures stained with 
Alizarin Red were provided, making it hard to judge the degree of calcium up-
regulation. 
Both groups of authors did not find any effects when BMP-7 was added to 
standard expansion media; only when BMP-7 was added to osteogenic media, 
the effects on MSCs have become prominent. Based on these findings it can be 
concluded that BMP-7 acts in synergy with other media components, potentially 
dexamethasone, leading to better osteoinduction [174}. In concordance, Shea 
et al showed that BMP-7 activity was enhanced in "nutrient-rich media", 
suggesting a potential autocrine mechanism of BMP-:-7 action [175], the idea 
also proposed by others [176]. In this work, the effect of BMP-7 on calcium 
production by MSCs grown in standard expansion media was not studied. This 
was based on the initial pilot results that were carried out prior to the 
experiments in this work which shown no osteogenic induction in standard 
media. Similar findings from the work by Shen et al [123] also found no effects, 
both consistent with Zhi et al study [174]. However, the effects of BMP-7 on 
MSC proliferation in standard conditions and the CFU-F colony counts were 
studied in this work and showed no effect on MSC proliferation. Shen et al 
actually found an inhibition of MSC proliferation with the addition of BMP-7 in 
vitro [123]. In concordance, Lavery et al [176], showed that the addition of BMP-
7 transiently attenuated cell cycle progression and proliferation of primary 
human MSCs. These combined data support an idea that BMP-7 on its own 
exerts no notable enhancing effects on MSC proliferation and its effects on 
MSC osteogenic differentiation are dependent on a synergy with other, yet 
unidentified, osteoinductive molecules [177}. 
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From the literature, it appears that no previous study has explored the 
responsiveness of MSCs from nonunion patients to BMP-7. In this study, the 
effects of BMP-7 on control MSCs and MSCs from nonunion patients were not 
observed at all. This was unexpected with the view of beneficial effects of BMP-
7 in treating nonunions in clinical trials [83, 152, 154, 172, 173]. To explore 
these observations further, more experiments were conducted involving 
uncultured MSCs from nonunion patients. It is well known that MSCs lose their 
potency following expansion [178] and it is possible that MSCs from nonunion 
patients lose their responsiveness to BMP-7 faster than MSCs from union 
patients, leading to no observed effects in experiments when cultured nonunion 
MSCs are used. Experiments with fresh MSCs involved no prior cultivation and 
were performed at the clonogenic level straight after BM plating. As mentioned 
above, the experiments studying osteogenesis were conducted in 
osteoinductive media only and experiments exploring proliferation were 
performed in expansion media only. In these experiments, the overall effects on 
MSC osteogenesis remained absent. The effects on MSC proliferation were 
donor-dependent. Those donors who had high CFU-F counts in the first place 
tended to up-regulate these counts further. When the whole group of patients 
was assessed for colony distributions however, BMP~7 appeared to have no 
effect. This effect on MSC proliferation was similar to the effects observed for 
union MSCs. Given these findings, one can become less optimistic as to the 
direct value of using BMP-7 in nonunion patients, because not only their MSC 
osteogenesis was unaffected, but their proliferation also. 
One requires to have in mind however, that in vitro experiments provide only 
first initial ideas and testing in other systems including animal models is needed 
to consolidate knowledge in this area [179,·180]. As an example of limitations of 
using in vitro assays for BMP-7 research, one can highlight the Neumann et all 
paper, who showed that culturing MSCs in 3-dimentional, rather than 2-
dimentional culture, can lead to their enhanced adipogenesis (and not osteo- or 
chondrogenesis) [181]. The experiments conducted in animal models are much 
more powerful. The experiments performed in a mouse model of tibial fractures 
have demonstrated the up-regulation of BMP-7 mRNA at later stages of healing 
(days 14-21), which can be described as "osteogenic" stages during which 
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calcified cartilage is resorbed and osteoblastic recruitment is most active [24] . 
So it is possible that the action of BMP-7 in vivo is linked to MSC recruitment 
activities rather than to their direct differentiation to osteoblasts. This is an 
attractive idea, but in the contrary to that Lu et al showed that recombinant 
BMP-7 did not actually recruit MSCs from the BM to the fracture sites in the 
mouse model used [182]. Interestingly, they showed that BMP-7 had a 
prominent chondrogenic effect [182], also observed in an in vitro study by Shen 
et al [123]. Another possible explanation for the discrepancy between the 
reported in vitro and in vivo stUdies lies in a more complicated nature of cellular 
and molecular interactions in vivo. It is very likely that BMP-7 exert its effects in 
cooperation with other BMPs and their inhibitors [179, 183]. The need of using 
supraphysiological concentration of BMP-7 in clinic may be due to high 
concentrations of BMP pathway inhibitors such as noggin [184] at the fracture 
sites. Based on this proposition, one can suggest that the way of reducing the 
cost of BMP-7 therapy for nonunion patients, which is indeed efficacious, is to 
interfere with its inhibitors at the fracture sites. This would be very interesting to 
test in a future in vivo study. Another potential solution, as proposed by Zhi et 
ai, is to further explore the synergy of BMP-7 with other pharmacological 
compounds such as steroids, in order to reduce "costs and complications 
associated with supra physiological dosage of rhBMPs in therapeutic protocols" 
[174]. Synergistic BMP pairs have been proposed as another solution [21]. 
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7.3 DISCUSSION ON MSC CIRCULATION 
Historically, it was considered that MSCs were 8M resident cells that could 
circulate to distant sites and lead to tissue repair following injury [92]. Several 
studies have reported MSCs in the circulation in both animal models and in man 
[17, 19, 185]. Shirley et ai, used autologous culture expanded, fluorescently 
labelled MSCs from New Zealand White rabbits to study the systemic 
recruitment capacity of MSCs to sites of bone fracture. MSCs were obtained 
from the tibia of the rabbits, culture expanded in osteogenic conditions and then 
fluorescently labelled. Ulnar osteotomy was performed to simulate fracture and 
48 hours later the MSCs were injected either intravenously, or into the sound 
tibia 8M cavity, or into the osteotomy gap. Another group was formed in which 
labelled MSCs were injected into the sound tibia 8M cavity 4 weeks prior to 
ulnar osteotomy and a control group in which no labelled MSCs were injected. 
They detected the labelled MSCs at the fracture gap in all but the control group 
3 weeks after the osteotmy and attributed their presence to the homing capacity 
of MSCs to site of fracture. Eghbali-Fatourech et al [185], attributed their 
generous detection of circulating MSCs in normal physiological conditions due 
to the fact that they have not relied on the plastic adherence property to isolate 
MSCs, but instead used flow cytometry and FACS to enrich for MSCs. 
Collectively, these studies might suggest a role for MSCs under normal 
physiological conditions and during tissue repair following injury, something that 
could be extremely important for fracture nonunion therapy development 
strategies. 
Moreover, several studies have argued that circulating MSCs or other stromal 
. cells could be responsible for the destructive nature of RA with polyarticular jOint 
erosion. The paradigm assumes that MSCs circulate but that their function in 
RA is altered and that this leads to severe jOint destruction [129, 130]. 
However several studies have failed to show MSCs in the circulation [18] or 
detected them at a very low concentration [19]. Jones and McGonagle [18] 
investigated the presence of circulating MSCs in the peripheral blood from 16 
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healthy individuals using multiparameter flow cytometry after enrichment for 
MSCs. Upon use of rigorous flow cytometric phenotypic criteria, they were 
unable to detect an MSC population in the circulation, but reported phagocytic 
cells of possible macrophage I monocytic nature. 
MSCs have been shown to be closely related to fat globules [85, 186]. It is also 
interesting to note that patients with major trauma to long bones can experience 
fat embolism [187], this present data supports the idea that trauma to the 
skeleton disrupts capillary beds in the bone and facilitates the egress of fat or 
MSCs or both into the circulation. In a recent study by Kumagai et ai, it was 
demonstrated that MSCs may home to sites of fractured femurs in the parbiotic 
mice model [188]. 
In this work, MSCs were not detected in the UL samples of neither the healthy 
donors nor patients with RA not on immunosuppressive therapy. However, they 
were detected in the UL and LL venous blood following reaming with RIA or in 
other cases in which skeletal trauma took place, suggestive of a biophysical 
translocation of MSCs from their 8M niche into the circulation. The concept 
proposed is similar to fat embolism reported following major long bone fractures 
and reaming [189] whereby MSCs are likely to enter the circulation in 
meaningful numbers only at times of skeletal trauma including surgical trauma. 
In total, the present data argues against recruitment of MSCs into the blood 
outside the setting of skeletal trauma. Given their low numbers, these circulating 
MSCs are unlikely to contribute significantly to fracture healing. 
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7.4 LIMITATIONS OF THIS STUDY 
Given the 2 year study period for this work, it was not possible to recruit patients 
for a prospective observational study of the CFU-F number and distribution of 
colony sizes following the initial fracture fixation, in anticipation of any healing 
complications that may arise during follow up. 
The biggest potential limitation of this study is the small patient cohorts used in 
some studies, particularly in the BMP-7 study. In general, patient recruitment 
into a nonunion study was determined by clinical constraints, mainly the limited 
number of cases available for recruitment, together with prioritizing trauma 
patients over "elective cases". Secondly, very stringent excluding criteria, 
particularly in relation to patients with advanced age were applied in order to 
carefully age and sex match all the groups under comparisons. 
Due to the high cost of recombinant BMP-7, the BMP-7 study had to be very 
carefully planned, with the important arm being the need to use at least two 
different concentrations of BMP-7 in order to discern dose-dependent effects. 
The highest dose of 300ng/ml of BMP-7 had to be used, as previous studies 
utilizing 100ng/ml had shown discrepancy in the results [123, 174]. Due to high 
cost of BMP-7, this resulted in the need to scale-down the number of 
experimental groups to a minimum (expanded union MSCs, expanded nonunion 
MSCs and uncultured nonunion MSCs). Indeed, BMP-7 was not tested in union 
non-expanded MSCs. and this would be very interesting to test in a follow-on 
study. Calcium assay was performed on day 14 post-induction; one very recent 
study suggested that testing at later time:points (day 35) could have yielded 
stronger effects [174]. The mere fact, that a longer than normal assay duration 
in the latter study was needed, fully confirm the data in this study that the 
effects of BMP-7 on cultured human MSCs are minimal. It has to be 
acknowledged however, that performing assays at two time-points (at 14 days 
post-induction and at a longer one) could have better addressed the issue 
whether or not MSCs from nonunion patients showed a delayed response to 
BMP-7. This can be also explored in a follow-on study. 
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In relation to the evaluation of the MSC reservoir in patients with nonunion, the 
imitations of this study can be described as follows. Firstly, colony size 
measurements based on a grid system are fairly subjective and an automated 
analysis would be more desirable. However, utmost effort was made to prove 
that colony sizes on the grid truly reflected the proliferative potential of colony-
forming MSCs. This was done by counting cells in selected colonies and 
converting these numbers to PDs or divisions of individual cells. Of note, an 
automated analysis was performed in one previous study [174] and results 
presented in this study are very comparable. Furthermore, assessment of the 
MSC numbers by flow cytometry was performed. One may suggest that another 
type of proliferation assay could be used to validate the colony size findings. 
These could have included proliferation assays like xtt or Vybrant assays [51], 
however the latter assays utilise culture-expanded MSCs whereas in this work, 
experiments were aimed to minimise any artefacts inherent to prolonged culture 
manipulations. Hence traditional colony assays initiated directly from the 8M 
aspirate were used [190], thus limiting the portfolio of downstream proliferation 
assays that could be used. 
The limitation of the circulation MSCs study can be described as an inability to 
obtain femoral blood samples from normal volunteers and rheumatoid arthritis 
patients for the aforementioned reasons. Ideally in the RIA group, blood 
samples should have been collected before and after reaming, but this was not 
ethically permissible especially for the femoral venous blood sample due to the 
possible complications from this procedure. Additionally, due to the extreme 
scarcity of CFU-F colonies it was not possible to expand them to a sufficient 
level in order to investigate them further - either by flow cytometry or using 
functional osteogenesis assays. The current results however, provide a good 
starting point as to what kind of average femoral blood volume needs to be 
collected in order to realistically expect sufficient quantities of MSCs to enable 
these more comprehensive studies (potentially several hundred millimetres 
which is unethical and impracticable). 
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7.5 FUTURE DIRECTIONS 
This research presented here highlights the strengths and weaknesses of in 
vitro assays to study disease and to model the effects of therapeutic agents on 
biology of bone cells and their progenitors. In the future, it would very interesting 
to use these assays to further model the interactions between BMP-7 and other 
candidate complimentary molecules (like other BMPs or steroids) to see if their 
combined effects would have enhanced osteogenesis of MSCs from nonunion 
patients. Additionally, it would be interesting to study similar effects on MSC 
chondrogenesis and their cytokine release, particularly in relation to those 
cytokines involved in MSC recruitment at the localleve!. The preliminary work in 
this thesis suggests that autologous MSCs obtained from locations distant from 
the nonunion sites may have defective capabilities. Therefore, it would be 
worthwhile to conduct a broader study of CFU-F dynamics in fracture patients 
aiming to using CFU-F colony size measurements as a predictive assay for 
fracture nonunion. If this stands true, it would be interesting to discover 
systemic circulating factor(s) responsible for this phenomenon, which would 
have allowed developing a predictive test based on serum analysis rather than 
BM aspirate which is much more invasive. 
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9.1 APPENDIX 1: ETHICS APPROVALS 
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Professor Giannoudis 
Consultant Orthopaedic Surgeon 
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St. James's University Hospital 
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NHS Trust 
Research & Development Directorate 
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Great George Street 
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West Yorkshire 
LSI 3EX 
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Re: L THT R&D Approval of Project No OR0617651 Biological properties of 
Mesenchymal Stem Cells in Fracture Healing 
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Form. 
As principal investigator you have responsibility for the design, management and 
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Chai rman Mart in Buckley Chie f Executive Neil McKay CB 
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R&D approval 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D approval of 
the research. 
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
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Yours sincerely 
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N HS Tr ust 
PATIENT INFORMATION SHEET 
Collection of Bone, Bone Marrow & Blood 
You are being invited to take part in a RESEARCH study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take the time 10 read the following infonnation carefully and discuss it 
with friends, relatives, and your GP if you wish. Ask us ifthere is anything that is not 
clear, or if you would like more infonnation. Take time to decide whether or not you 
wish to take part. 
Consumers for Ethics in Research (CERES) publish a leafl et entitled "medical 
Research and You". TIlis leaflet gives more infonnation about medical research and 
looks at some questi ons you may want to ask. A copy may be obtained from your 
study doctor. 
Thank you for reading this. 
1. Wllat is tile purpose o/Ille slIIdy? 
Special cells in the body tenned Mesenchymal Stem Cells (MSCs) can make bone, 
cartilage, bone, muscle, tendon and ligament. MSCs have been found in all tissues to 
date but just how they work is still not understood. There is interest in the use of 
MSCs as a way of repairing damaged joints. Our research is aimed at understanding 
how these cells work in health and in disease. 
2. Wily hOl'e I bem chosell? 
You suffer from a fractured bone. At surgery we would like to take a small sample 
of your bone and bone marrow from the fracture site. This tissue is sitting at the 
fracture site and is nonnal!y discarded during the operation when the fracture site is 
being cleaned and repaired. 
Taking bone, bone marrow and blood at the time of surgery will not cause you furth er 
discomfort and wi ll not delay healing ill allY way. 
3. Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, you will 
be given this infonnation sheet to keep and be asked to sign a consent fonn . If you 
decide to take part, you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care that you receive. 
4. Wllat will happell to me if I lake part? 
If you decide to take part you will be asked to sign an infonned consent sheet, and 
you will be given a copy oftlle infonnation and the signed consent sheet to keep. You 
will be asked to donate a. small amount of bone marrow nomlal1y discarded during 
your operation. 
5. WIlDt do Illave 10 do? 
Apart from donating a small amount of bone, bone marrow aJld blood for research, 
tllere are no other requirements/tests. 
Collection o/Bone. Bone Marrow & Blood 
Patient in/olmQtion and consent/onn Version I(A July 2006 
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It is very important, when giving your medical history to the doctor, that you tell 
him/her wheOler or not you are regularly taking any medicine. Taking certain types of 
medicines means we will not be able to recruit you into the study. 
6. What are the .~ide effecJs of taking part? 
TIlere are no side effects. TIle collection of the bone, bone marrow and blood is of 
Ii mi ted q uan ti t y. 
7. What are the possible bellefus of taking part? 
You wi ll not benefit directly from taking part in this research and all other aspects of 
your care will be the same as if you did not take part. 
8. What ifsometl,illg goes wrOl'g? 
If you are hanned by taking part in tJlis research, there are no special compensation 
arrangements. If you are harmed due to someone 's negli gence, Olen you may have 
grounds for a legal action but you may have to pay for it. Regardless of this, if YOll 
wish to complain about any aspect of the way you have been approached or treated 
during the course of tJlis study, the nonnal NHS complaints mechanism may be 
available to you. 
9. Will my taking part in this study be kept cOllfidelltiaL? 
As soon as the bone, bone marrow and blood are taken from you, all information that 
identifies you will be removed so that you cannot be recognised. 
10. What will happen to the resllits of the smdy? 
At the end of the study, the results will be written into a scientific paper for 
publication in a scientific joumal. 
11. Who is organising the researd,? 
This project is being organized by Doctors of Leeds General Infmnary and Leeds 
Institute Molecular Medicine under the supervision and support of Leeds University. 
J 2. Who has reviewed thi..~ stll4v? 
This study has been reviewed by the independent ethics committee called tile Leeds 
(East) ethics committee. This committee is appointed to determine that research 
studies are ethical and do not impair the rights or well-being of patients. We have 
received approval by tJlis committee to be able to do this research study. 
13. COlltact for further ;,iformation 
Please do not hesitate to contact your GP or any other independent person if you need 
advice. For further information on the study please contact Professor Peter 
Giannoudis at 0113 3466460. 
Collection a/Bone. Bone Marrow & Blood 
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PATIENT C ONSENT FORM 
CoUectloll of BOlle, BOlle Marrow & Blood 
Prof Peter Giannoudi s 
Patient Name: ....................... .. .. .................... ....... .. 
Patient Identi fica tion Number: .. ........ ............ .. .......... .. 
Please circle as appropriate 
I . ) have read the patient information sheet for the above study. YesINo 
2. I have had the opportunity to ask questions about the study and to discllss it with 
family and fri ends if) so wish to. Yes/No 
3. I understand the purpose oftJle study, and how I will be involved. Yes/No 
4. I understand, and accept, that if I take part in the study I may not gain direct 
personal benetit from it. Yes/No 
5. ] understand that all information collected in the study will be held in confidence 
and that, if it is presented or published, all my personal detai ls will be removed. 
Yes/No 
6. I give permission for responsible individuals from regulatory authorities to have 
access to my medical notes where it is relevant to my taking part in the research. 1l1is 
is on the underst.anding that no personal detai ls which might identify me will be 
presented or published without my pemlission. Yes/No 
7. ) confirm that I will be taking part in this study of my own free will, and I 
understand that I am free to withdraw from the study at any time withom giving a 
reason and without affecting my future care or legal rights. Yes/No 
8. I have spoken to Dr .................. .. 
9. ) agree to take part in this research study. 
PATIENT: 
Signed : ......... .. .. .. . ..... ...... ..... ll!!!!li.. .... .... .. ... .. . 
Name (BLOCK CAPITALS): .. ......... ................ .. 
Investigator/Sub-investigator 
I have exnlalned the study to the above named partlclnant and he/she has 
indicated his/her ,,·jlJingness to participate 
Signed: ..... .. . .. ...... . ......... . .... .Q!!!£.:. ....... ......... . 
Name (BWCK CAPITALS): ................. . ..... ... .. . 
Collection o/Bone, BoneA/arrow & Blood 
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PATIENT INFORMATION SHEET 
Functional characterisation of the genes and proteins involved in the 
development and severity of autoimmune and (auto) inflammatory 
diseases. 
PART 1 
1. Invitation 
You are being Invited to take part In a research study. Before you decide whether or not 
to take part, It Is Important for you to understand why the research Is being done and 
what It will Involve. Please take time to read the following Information carefully, and 
discuss It with others If you wish. 
PART 1 tells you the purpose of this study and what will happen to you If you take part. 
PART 2 gives you more detailed Information about the conduct of the study. 
Ask us If there Is anything that Is not clear. or If you would like more Information. Take 
time to decide whether or not you wish to take part. 
2. What Is the purpose of the study? 
Many autoimmune and (auto)inflammatory diseases. such as rheumatoid arthritis. systemic 
lupus erythematosus. vasculitis and the connective tissue diseases are associated with the 
presence of specific changes in either an individual's genetic makeup or their immune system. 
This can lead to alterations in the different components of the immune system or in the proteins 
that are produced by these genes. We feel these changes may be important for the 
development of either the disease itself. specific antibodies! complications or that they may even 
predispose to or even help us predict more severe disease. We would like to perform some 
further research to gain a better understanding of their biology and how they may contribute to 
these various diseases. 
3. Why have I been chosen? 
You have been chosen because you have a specific autoimmune or Inflammatory disease that 
we are interested in studying further. Alternatively. you may have donated a sample for one of 
our previous studies and we have already characterised some of your genes. In this study we 
would like to use your white blood cells to determine if this genetic variant affects the way your 
cells work. We would also like to store some of your white blood cells and additional components 
01 your blood. such as the proteins and a sample 01 your DNA and urine. Otherwise. you may be 
having some fluid drained from one of your jOints. an arthroscopy or biopsy to help with the 
diagnosis of your condition. or as part 01 your treatment. We would like to be able to use this 
fluid anellor any surplus tissue samples. which would otherwise be thrown away. for research 
purposes. These samples will only be used in future studies that continue with this agreed line of 
research. In order to give us a permanent source of specific genes and proteins we may also like 
to make some cell· lines from specific proteins or cells from your blood in the laboratory. 
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4. Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, you will be given 
this information sheet to keep and be asked to sign a consent form . If you decide to take part, 
you are still free to withdraw at any time and without giving a reason. This will not affect the 
standard of care you receive. 
5. What will happen to me If I take part? 
If you decide to take part you will asked to sign an informed consent sheet, and you will be given 
a copy of the information sheet to keep. You will be asked to donate a sample of blood (up to 
50mls), which will be taken at the same time as your routine clinic blood tests. Alternatively, we 
may ask for a sample of your urine or the ability to use the surplus joint fluid or tissue removed 
as part of your routine NHS treatment. Taking part will therefore not involve any extra visits to 
the clinic. 
The blood sample will be used for genetic testing , but this is purely for research purposes and 
you will not be told the results of the tests on your samples. Insurance companies, however, may 
ask you whether you have previously had genetic tests. Should this situation arise, we advise 
you to answer "no" in your Insurance policy application form . This is because the genetic tests 
we are doing, are purely for research purposes and have no bearing whatsoever on your current 
or future insurance policies. 
6 What do I have to do? 
Apart from donating a small volume of blood for research, there are no other requirements! tests. 
7. What are the side effects of any treatment received when taking part? 
You may develop a bruise at the site of the needle but, as stated above, taking part in this study 
does not involve any additional blood tests. 
8. What are the possible benefits of taking part? 
You will not benefit directly from taking part in this research, and all other aspects of your care 
will be the same as if you did not take part. 
g. What If there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your question . If you remain unhappy and wish 
to complain formally, you can do this through the NHS Complaints Procedure. Details 
can be obtained from the hospital. 
In the event that something does go wrong and you are harmed during the research study there 
are no special compensation arrangements. If you are harmed and this is due to someone's 
negligence then you may have grounds for a legal action for compensation but you may have to 
pay your legal costs . The normal National Health Service complaints mechanisms will still be 
available to you. 
10. Will my taking part In this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The 
details are included in Part 2. 
11. Contact Details 
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Please do not hesitate to contact your GP or any other independent person if you need 
advice. For further information on the study please contact Dr Ann W Morgan or 
Professor Dennis McGonagle on extension 0113 206 5117. 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
PART 2 
12. Will my part in this study be kept confidential? 
If you consent to take part in th is study, the records obtained while you are in this study as well 
as related health records will remain strictly confidential at all times. The Information will be held 
securely on paper and electronically at your treating hospital and the University of Leeds, the 
main team managing this research under the provisions of the 1998 Data Protection Act. Your 
name wlll not be passed to anyone else outside the research team or the sponsor, who is not 
involved in the research. 
Information will be transferred from your hospital site to the team at the University of Leeds 
organizing the research, to enable processing of blood samples, this will be done by mail, 
however your name will only appear on your consent form and blood sample until it is separated 
and stored. All other records will have your name removed and will only feature your initials and 
date of birth. 
Your records will be available to people authorised to work on the trial but may also need to be 
made available to people authorised by the Research Sponsor, which is the organisation 
responsible for ensuring that the study is carried out correctly. A copy of your consent form may 
be sent to the Research Sponsor during the course of the study. By signing the consent form 
you agree to this access for the current study and any further research that may be conducted in 
relation to it, even if you withdraw from the current study. 
The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority and Independent Ethics Committee; this is to ensure that the study is 
carried out to the highest possible scientific standards. All will have a duty of confidentiality to 
you as a research participant. 
In line wlth Good Clinical Practice guidelines, at the end of the study, your data will be securely 
archived for a minimum of 15 years. Arrangements for confidential destruction will then be made. 
20. What will happen to any samples I give? 
Once it is sent to the University of Leeds, your blood sample will anonymised and separated into 
its component parts so that some of your DNA, serum and cells will be stored to form part of our 
"disease sample repository" so that we can use it in current and future genetic and 
immunological studies. Any additional studies will be SUbject to additional independent ethical 
committee review. 
21 . Will any Genetic testing be done? 
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Yes, once anonymised your DNA will be used in genetic testing aimed at finding out which 
genes are important in both the development and severity of a number of autoimmune and 
(auto)inllammatory diseases. Your DNA will only be used in future studies which continue the 
research themes outlined above. 
22. What will happen to the results of this research? 
The results of the studies using the "disease sample repository" will usually be published in a 
medical journal or be presented at a scientific conference. The data will be anonymous and 
none of the patients involved in the study will be identified in any report or publication. 
23. Who is organising and funding this research? 
This project is partly being funded by grants from the National Institute for Health Research, 
Arthritis Research Campaign. Research into Ageing and the University of Leeds. 
24. Who has reviewed the study? 
This study was given favourable ethical oPinion for conduct in the NHS by Leeds (East) 
Research Ethics Committee. This committee is appointed to detenmine that research studies are 
ethical and do not impair the rights or well-being of patients. We have received approval by this 
committee to be able to do this research study. 
25. Contact for further information 
You are encouraged to ask any questions you wish, before, during or alter your treatment. If you 
have any questions about the study, please speak to your study nurse or doctor, who will be 
able to provide you with up to date information about the procedure(s) involved. If you wish to 
read the research on which this study is based, please ask your study nurse or doctor. If you 
require any further information or have any concerns while taking part in the study please 
contact one of the following people: 
Dr Ann W Morgan or Professor Dennis McGonagle on 0113 2065117 
Alternatively if you or your relatives have any questions about this study you may wish to contact 
your GP or an organisation that is independent of the hospital at which you are being treated: 
Arthritis Research Campaign (arc) is a registered charity providing infonmation about all aspects 
of arthritis for patients and their families. They can provide useful booklets. You can contact 
them on OB70 B50 5000, or access their web site at http://Www.arc.org.uk 
II you decide you would like to take part then please read and sign the consent form. You will be 
given a copy of this Information sheet and the consent form to keep. A copy of the consent form 
will be filed in your patient notes, one will be filed with the study records and one may be sent to 
the Research Sponsor. 
You can have more time to think this over If you are at all unsure. 
Thank you for taking the time to read this Infonmation sheet and to consider this study. 
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PATIENT CONSENT FORM 
Functional characterisation of the genes and proteins involved in the 
development and severity of autoimmune and (auto) inflammatory diseases. 
Patient 10: .............. .... ..... .. Initials: . ..... .... ..... ........ ... .. . Date of Birth : .. ... ............ ... . 
Patient initial each point 
1. I confirm that I have read and understand the information sheet dated 26.03 .2009 
(version 3.0) for the above study, and have had the opportunity to ask questions. I 
understand that my participation is voluntary and that I am free to withdraw at any 
time without my medical care or legal rights being affected. I agree to take part in 
the study. 
2. I understand that my medical records may be looked at by authorised individuals 
from the Sponsor for the study, the UK Regulatory Authority or the Independent 
Ethics Committee in order to check that the study is being carried out correctly. I 
give pennission, provided that strict confidentiality is maintained, for these bodies 
to have access to my medical records for the above study and any further 
research that may be conducted in relation to it. I also give permission for a copy 
of my consent form to be sent to the Sponsor for the study. 
3. I understand that even if I withdraw from the above study, the data and samples 
collected from me will be used in analysing the results of the study, unless I 
specifically withdraw consent for this. I understand that my identity will remain 
anonymous. 
4. I consent to the storage Including electronic, of personal Infonnatlon for the 
purposes of this study. I understand that any information that could identify me will 
be kept strictly confidential and that no personal infonnation will be included in the 
study report or other publication . 
5. I agree to the samples and cell lines being stored for future research . 
6. I agree to have genetic tests done on samples for research purposes. 
Name of the patient 
Name of the Investigator 
taking written consent 
Patient's signature and the date the patient signed the 
Consent form 
Investigator's signature and date the Investigator signed the 
consent form 
Orfglnallo be retained and IIled In lhe site lile. 1 copy 10 pallenl, 1 copy 10 be flied In pallent's noles, 1 copy 
lor Sponsor 
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PATIENT INFORMATION SHEET 
(HEALTHY CONTROLS) 
Functional characterisation of the genes and proteins involved in the 
development and severity of autoimmune and (auto) inflammatory 
diseases. 
PART 1 
1. Invitation 
You are being Invited to take part In a research study. Before you decide whether or not 
to take part, It Is Important for you to understand why the research Is being done and 
what It will Involve. Please take time to read the following Information carefully, and 
discuss It with others If you wish. 
PART 1 tells you the purpose of this study and what will happen to you If you take part. 
PART 2 gives you more detailed Information about the conduct of the study. 
Ask us If there Is anything that Is not clear, or If you would like more Information. Take 
time to decide whether or not you wish to take part. 
2. What Is the purpose of the study? 
Many autoimmune and (auto)inflammatory diseases. such as rheumatoid arthritis, systemic 
lupus erythematosus, vasculitis and the connective tissue diseases are associated with the 
presence of specific changes in either an individual 's genetic makeup or their immune system. 
This can lead to alterations in the different components of the immune system or in the proteins 
that are produced by these genes. We feel these changes may be important for the 
development of either the disease itself, specific antibodies! complications or that they may even 
predispose to or even help us predict more severe disease. We would like to perform some 
further research to gain a better understanding of their biology and how they may contribute to 
these various diseases. 
3. Why have I been chosen? 
In studies of this type we need to compare the genes, proteins and components of the immune 
system In people with the diseases we are Interested In compared to those people of the same 
age who do not have the disease ('controls"). You have been Identified as someone who is 
unlikely to have one of these conditions and we would like to store some of your blood, such as 
the white blood cells, proteins and sample of your DNA, andl or a urine sample to form part of a 
' control" sample bank. These samples will only be used in future studies that continue with this 
agreed line of research. 
4. Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, you will be given 
this information sheet to keep and be asked to sign a consent form . If you decide 10 take part, 
you are still free 10 withdraw at any lime and wilhout giving a reason. 
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5. What will happen to me If I take part? 
If you decide to take part you will asked to sign an informed consent sheet, and you will be given 
a copy of the information sheet to keep. You will be asked to donate a sample of blood (up to 
50mls) . Alternatively, we may ask for a sample of your urine. 
The blood sample will be used for genetic testing, but this is purely for research purposes and 
you will not be told the results of the tests on your samples. Insurance companies, however, may 
ask you whether you have previously had genetic tests. Should this situation arise, we advise 
you to answer "no" in your insurance policy application form. This is because the genetic tests 
we are doing, are purely for research purposes and have no bearing whatsoever on your current 
or future insurance policies. 
6. What do I have to do? 
Apart from donating a small volume of blood for research, there are no other requirements! tests. 
7. What are the side eHects of any treatment received when taking part? 
You may develop a bruise at the site of the needle but, as stated above, taking part in this study 
does not involve any additional blood tests. 
S. What are the possible benefits of taking part? 
You will not benefit directly from taking part in this research , and all other aspects of your care 
will be the same as If you did not take part. 
9. What If there Is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your question. If you remain unhappy and wish 
to complain formally, you can do this through the NHS Complaints Procedure. Details 
can be obtained from the hospital. 
In the event that something does go wrong and you are harmed during the research study there 
are no special compensation arrangements. If you are harmed and this is due to someone's 
negligence then you may have grounds for a legal action for compensation but you may have to 
pay your legal costs. The normal National Health Service complaints mechanisms will still be 
available to you . 
10. Will my taking part In this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The 
details are included in Part 2. 
11. Contact Details 
Please do not hesitate to contact your GP or any other independent person if you need advice. 
For further information on the study please contact Dr Ann W Morgan (0113 34384t4) or Dr 
Dawn Cooper or Dr Sarah Mackie (01 t3 3438413) . 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
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PART 2 
12. Will my part in this study be kept confidential? 
If you consent to take part in this study, the records obtained while you are in this study as well 
as related health records will remain strictly confidential at all times. The information will be held 
securely on paper and electronically at your treating hospital and the University of Leeds, the 
main team managing this research under the provisions of the 1998 Data Protection Act. Your 
name will not be passed to anyone else outside the research team or the sponsor, who Is not 
involved in the research . 
Information will be transferred from your hospital site to the team at the University of Leeds 
organizing the research, to enable processing of blood samples, this will be done by mail, 
however your name will only appear on your consent form and blood sample until it is separated 
and stored. All other records will have your name removed and will only feature your initials and 
date of birth. 
Your records will be available to people authorised to work on the trial but may also need to be 
made avai lable to people authorised by the Research Sponsor, which is the organisation 
responsible for ensuring that the study Is carried out correctly. A copy of your consent form may 
be sent to the Research Sponsor during the course of the study. By signing the consent form 
you agree to this access for the current study and any further research that may be conducted in 
relation to It, even If you withdraw from the current study. 
The information collected about you may also be shown to authorised people from the UK 
Regulatory Authority and Independent Ethics Committee; this is to ensure that the study Is 
carried out to the highest possible scientific standards. All will have a duty of confidentiality to 
you as a research participant. 
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely 
archived for a minimum of15 years. Arrangements for confidential destruction will then be made. 
20. What will happen to any samples I give? 
Once it is sent to the University of Leeds, your blood sample will anonymised and separated into 
its component parts so that some of your DNA, serum and cells will be stored to form part of our 
"disease sample repository" so that we can use it in current and future genetic and 
immunological studies. Any additional studies will be SUbject to additional independent ethical 
committee review. 
21. Will any Genetic testing be done? 
Yes, once anonymised your DNA will be used in genetiC testing aimed at finding out which 
genes are Important In both the development and severity of a number of autoimmune and 
(auto)inflammatory diseases. Your DNA will only be used in future studies which continue the 
research themes outlined above. 
22. What will happen to the results of this research? 
The results of the studies using the "disease sample repository" will usually be published in a 
medical journal or be presented at a scientific conference. The data will be anonymous and 
none of the patients involved in the study will be identified in any report or publication. 
23. Who is organising and funding this research? 
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This project is partly being funded by grants from the National Institute for Health Research, 
Arthritis Research Campaign, Research into Ageing and the University of Leeds. 
24. Who has reviewed the study? 
This study was given favourable ethical oplnton for conduct in the NHS by Leeds (East) 
Research Ethics Committee . This committee is appointed to determine that research studies are 
ethical and do not impair the rights or well-being of patients. We have received approval by this 
committee to be able to do this research study. 
25. Contact for further information 
You are encouraged to ask any questions you wish , before, during or after your treatment. If you 
have any questions about the study, please speak to your study nurse or doctor, who will be 
able to provide you with up to date information about the procedure(s) involved. If you wish to 
read the research on which this study is based, please ask your study nurse or doctor. If you 
require any further information or have any concerns while taking part in the study please 
contact one of the following people: 
Dr Ann W Morgan 01132065117 
Alternatively if you or your relatives have any questions about this study you may wish to contact 
your GP or an organisation that is Independent of the hospital at which you are being treated: 
Arthritis Research Campaign (arc) is a registered charity providing information about all aspects 
of arthritis for patients and their families . They can provide useful booklets. You can contact 
them on 0870 850 5000, or access their web site at http://www.arc.org.uk 
If you decide you would like to take part then please read and sign the consent form. You will be 
given a copy of this information sheet and the consent form to keep. A copy of the consent form 
will be filed in your patient notes, one will be filed with the study records and one may be senllo 
the Research Sponsor. 
You can have more time 10 think this over if you are at all unsure. 
Thank you for taking the time to read this information sheet and to consider this study. 
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CONSENT FORM 
Functional characterisation of the genes and proteins involved in the 
development and severity of autoimmune and (auto) inflammatory diseases. 
Patient 10: ....... ...... . .. ... ... .. . Initials: ... .. ........ ... .... ........ . Date of Birth : .................... . 
Patlenllnltlal each point 
1. I confirm that I have read and understand the information sheet dated 26.03 .2009 
(version 3.0) for the above study, and have had the opportunity to ask questions. I 
understand that my participation is voluntary and that I am free to withdraw at any 
time without my medical care or legal rights being affected. I agree to take part in 
the study. 
2. I understand that my medical records may be looked at by authorised individuals 
from the Sponsor for the study, the UK Regulatory Authority or the Independent 
Ethics Committee in order to check that the study is being carried out correctly. I 
give permission , provided that strict confidentiality is maintained, for these bodies 
to have access to my medical records for the above study and any further 
research that may be conducted in relation to it. I also give permission for a copy 
of my consent form to be sent to the Sponsor for the study. 
3 . I understand that even if I withdraw from the above study, the data and samples 
collected from me will be used In analysing the results of the study, unless I 
specifically withdraw consent for this. I understand that my identity will remain 
anonymous. 
4. I consent to the storage including electroniC, of personal information for the 
purposes of this study. I understand that any information that could identify me will 
be kept strictly confidential and that no personal Information will be Included In the 
study report or other publication . 
5. I agree to the samples and cell lines being stored for future research. 
6. I agree to have genetic tests done on samples for research purposes. 
Name of the patient 
Name of the Investigator 
taking written consent 
Patient's signature and the date the patient signed the 
Consent form 
Investigator's Signature and date the Investigator signed the 
consent form 
Ortglnal to be retalnad and Illed In the aile Ilia. 1 copy to patient, 1 copy to be Iliad In pallent's not88, 1 copy 
lor Sponsor 
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